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polyunsaturated fatty acid levels during pregnancy and childhood lipids and insulin 











Cardiovascular disease is the leading cause of death globally.1   -
provement in cardiovascular health, coronary heart disease remains responsible for 
17.3 million deaths per year.1 The developmental origins hypothesis suggests that 
cardiovascular diseases have their origins in prenatal life and in early childhood.2 
 ǡ        -
ment, lead to permanent adaptations in the structure, physiology and function of 
various organ systems. This early programming contributes to short-term survival, 
but increases the susceptibility of cardio-metabolic diseases later in life. Maternal 
ϐǤ3
      ϐ  
ǦǤǡϐ
published in 1976 demonstrated the effects of intrauterine deprivation on subse-
Ǥ4ǡϐ
ǡϐ
that undernutrition during gestation increases the risk of many diseases, including 
obesity, heart disease, and diabetes. This study has provided crucial support and 
     ϐ      
Ǥǡ-
        ϐ
provision of nutrients during pregnancy results in long-lasting effects on the health 
of mothers and their children. Thus, this suggests that improved maternal nutrition 
with essential nutrients during gestation may reduce the risk of chronic diseases in 
Ǥǡϐϐ-
ents on offspring outcomes.




as saturated fatty acids (SFAs), while those containing carbon-carbon double bonds 
ϐǡȋ	Ȍ
ȋ	ȌǤ5	ǡ






 ǡ   Ǧ͸	   Ǥ 	
and their derivatives have important roles in cell membrane synthesis and regula-
Ǥ
ǡǯǡ  Ǥ
molecules are important for the regulation of several cellular processes, including 
ϐǡ ǡ   Ǥ7 In adult populations, 
        	 	 




During pregnancy, the fetus depends on maternal fatty acids availability.11 Fatty 
acids can cross the placental syncytiotrophoblast as free fatty acids derived from 
triglycerides and phospholipids. This process involves several fatty acid transport 
and binding proteins.12	-




supplementation during pregnancy results in higher birthweight and a decreased 
risk of preterm delivery.16ǡϐ
ǦǤ
In summary, maternal malnutrition during pregnancy may adversely affect long 
ǦǤ  ǡ
fatty acids status is an important factor associated with fetal development and birth 
outcomes. Identifying the associations of maternal fatty acids status during pregnan-
cy with childhood cardio-metabolic outcomes, may help to develop future preventive 
strategies that improve cardio-metabolic health in future generations by optimizing 
maternal nutritional status during pregnancy. Therefore, studies presented in this 
thesis were designed to identify the associations of maternal fatty acids status during 
pregnancy with cardio-metabolic health outcomes of the mothers and their children. 






associated with adverse maternal and fetal pregnancy outcomes.17 
ǡϐȋȌη͵ͲȀ2, is a risk factor for obstetric 
complications, such as gestational diabetes, preeclampsia and adverse birth out-
comes.18,19          
and offspring outcomes.20 During pregnancy, both higher prepregnancy BMI and 
 
sensitivity and therefore decreased ability of insulin to supress lipolysis, which 
results in increase free fatty acid concentrations.21
that a higher BMI during pregnancy is associated with higher levels of SFA and lower 
Ǧ͵	Ǥ22,23 It has also been suggested that obese women appear to have 
    Ǧǡ   
  ϐǤ24ǡ     -
 
during pregnancy with different maternal fatty acids levels. 
Vascular adaptations during pregnancy
Gestational hypertensive disorders are the most common medical problem during 
ǡ   ͹Ψ   Ǥ    
Figure 1.1. Ǧ
health of mothers and their children
	
	
Prepregnancy body mass index, gestational 
weight gain 
				




































cause of maternal, fetal and neonatal morbidity and mortality.25,26 Animal studies 
demonstrated that higher intake of SFAs during pregnancy may cause placental 
ϐǡ -
nancy-related maternal hemodynamic maladaptation and gestational hypertensive 
disorders.27 The role of fatty acids on gestational hypertensive disorders in human 
pregnancy is poorly studied. During pregnancy, it has been suggested that higher 
  		ǡ  	ǡ Ǧ͵	ǡ
are associated with higher maternal blood pressure.14,15 Thus far, results of studies 
focused on the associations of maternal fatty acids and gestational hypertensive 
disorders seem to be inconsistent and most studies have assessed only total free 
fatty acids, while individual fatty acids have not been well studied.28 Also, not much 
is known about direct effect of fatty acids on maternal blood pressure and placental 
Ǥǡ
maternal fatty acid levels with hemodynamic adaptations during pregnancy and the 
occurrence of gestational hypertensive disorders may provide further insight in the 
pathways underlying these associations.
Childhood outcomes
PUFAs and offspring body composition
Ǥ29ǡ
maternal intake of nutrients contributes to early adaptations in fetal development.30 
	          	 
 ϐ       
proliferator-activated receptors, which promote adipogenesis.31
Ǧ͵	Ǣ
of studies are inconsistent.32-34   











PUFAs and offspring cardio-metabolic outcomes
Ǧ
offspring cardio-metabolic health.37 Several studies during pregnancy have shown 
	   ǡ 
cholesterol and insulin levels in children.38-40ǡ  
   	     Ǧ  






General aim of this thesis
The general aim of this thesis was to identify the associations of maternal plasma 
fatty acid levels during pregnancy with maternal hemodynamic adaptations during 
pregnancy and cardio-metabolic outcomes in childhood.
General design
The studies presented in this thesis were embedded in the Generation R Study, a 
population based prospective cohort study from fetal life until young adulthood in 
Rotterdam, The Netherlands.41 The Generation R Study is designed to identify early 
environmental and genetic determinants of growth, development and health in fetal 
life and childhood. All pregnant women living in the study area with a delivery date 
ʹͲͲʹʹͲͲ͸Ǥ-
rolment was aimed at early pregnancy, but was possible until the birth of the child. In 
ǡͻǡ͹͹ͺǡͺͺͺͲȋͻͳΨȌ
during pregnancy (Figure 1.2). Assessments were planned in early pregnancy (<18 
weeks of gestation), mid-pregnancy (18 - 25 weeks of gestation) and late pregnancy 
ȋηʹͷ  Ȍǡ     ǡ 







diovascular follow-up measurements at the age of 6 years. Measurements during this 
visit included anthropometrics, body composition, cardiovascular development and 
blood sample collection.
Outline of this thesis
ǤChapter 
2, studies on maternal fatty acids status during pregnancy on gestational adaptations 
are described. In Chapter 2.1ǡ
Figure 1.2. Design and data collection in the Generation R Study
			




 multiple fetal growth and placental vascular ultrasounds, multiple 
maternal weight and blood pressure measurements, parental body mass index 



















: child anthropometrics 

Parental and child health, lifestyle habits  
			
	
 anthropometrics, body fat distribution, blood 











Infant subcutaneous fat measures  




           
mid-pregnancy. The associations of maternal plasma fatty acid concentrations with 
longitudinal blood pressure development and placental vascular function through-
out pregnancy and the risks of gestational hypertensive disorders are described in 
Chapter 2.2. 
In Chapter 3, we present studies focused on the associations of maternal n-3 and 
Ǧ͸	ǦǤ-
Ǧ͵Ǧ͸	 during pregnancy with 
infant subcutaneous fat mass measures are presented in Chapter 3.1. In Chapter 3.2 
and 3.3ǡǦ͵Ǧ͸	 
during pregnancy are associated with childhood adiposity and childhood blood pres-
sure, respectively. Chapter 3.5 describes the association of maternal plasma n-3 and 
Ǧ͸	 during pregnancy with lipid and insulin levels in childhood.
Finally, Chapter 4 provides a general discussion in which the studies described in 
   ǡ   
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 ͳ͸Ǥ Ǧ ǡ  ǡ 
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 -
saturated fatty acid intake during pregnancy on maternal, infant, and child health outcomes: a 
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in seven-year-old children: relations with birth weight and the polyunsaturated fatty acid content 
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   Ǥ     
 
concentrations in mid-pregnancy. This study was embedded in a population-based 
ͷǡ͸͵͸Ǥ
Ǥ
     ȋ	Ȍǡ   ȋ	Ȍǡ
Ǧ͵ȋǦ͵	ȌǦ͸ȋǦ͸
	ȌʹͲǤͷȋͻͷΨǣͳ͹ǤͳȂʹͶǤͻȌǤ
multivariate linear regression models. As compared to normal weight women, obese 
women had higher total SFA concentrations [difference: 0.10 standard deviation (SD) 
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risks of adverse pregnancy outcomes, including gestational hypertensive disorders, 
gestational diabetes, fetal death and large size for gestational age infants.11-14 Recent 
 
are also associated with adverse cardiovascular outcomes in the offspring.14,15 The 
mechanisms underlying these associations may involve fetal cardiovascular and 
      ϐ  
the placenta and fetus.16
and insulin resistance during pregnancy, which may lead to increased circulating free 




nant women suggested that women who were obese before pregnancy had lower 
ǡǦ͵	ǡǡǦ͸
	ǡǡǦ͵	ǡ
Ǥ20 This study did not have information 
on other fatty acid concentrations available. 
ǡ    Ǧ    
ͷǡ͸͵͸ǡ        
weight gain with plasma fatty acid concentrations in mid-pregnancy.
Methods
Study design
This study was embedded in the Generation R Study, a population-based prospective 
cohort study from foetal life to adulthood in Rotterdam, the Netherlands.21,22 The 
   
 ȋ ͳͻͺǤ͹ͺʹȀʹͲͲͳȀ͵ͳȌǤ     Ǥ 
 ʹͲͲʹ ʹͲͲ͸-




and gave birth to singleton live born children. Mid-pregnancy fatty acids concentra-
tions were measured among 5,636 women (Flow chart is given Figure 2.1.1).
Prepregnancy body mass index and gestational weight gain
At enrollment, we measured height (cm) and weight (kg) without shoes and heavy 
ǡ     ȋȀ2ȌǤ   
     Ǥ     ǡ
ͷʹǤ͵Ψ        ͳͶǤ -
  ǡ   ǡ  
enrollment was 0.95 (P δͲǤͲͲͳȌǤ  -
ͶȋȏδʹͲǤͲȀ2ȐǡȏʹͲǤͲȂʹͶǤͻȀ




Figure 2.1.1. Flow chart of the participants
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ed and transported to the Division of Metabolic Diseases and Nutritional Medicine, 
ǤǯǡǤ
thawed, the analysis of plasma glycerophospholipid fatty acids was performed by a 
sensitive and precise high throughput method. This method is suitable for applica-
tions in large epidemiological studies.24ϐǡ
selected fatty acids for our analyses, which have been associated with the risk of 
cardiovascular and metabolic outcomes in adults, and pregnancy outcomes.25-30 Se-
lected saturated fatty acids included total SFA concentrations, myristic acid (C14:0), 
palmitic acid (C16:0) and stearic acid (C18:0). Monounsaturated fatty acids included 
 	 ǡ   ȋͳ͸ǣͳ͹Ȍ    ȋͳͺǣͳͻȌǤ
Ǧ͵	ǡȽǦ
ȋǡ ͳͺǣ͵͵Ȍǡ   ȋǡ ʹͲǣͷ͵Ȍ   






level, ethnicity, parity, smoking, alcohol consumption and folic acid supplement by 







continuously and in categories, with fatty acid concentrations during pregnancy using 










eicosapentaenoic acid.33       





weight gain for the associations with plasma fatty acid concentrations. Since we did 
  ϐ ǡ        

categories. Because of the correlation between the different fatty acids, we did not 
apply correction for multiple testing. In order to reduce potential bias associated 
with missing data and to maintain statistical power, we performed multiple imputa-
tions of missing covariates by generating 5 independent datasets using the Markov 





Table 2.1.1 shows that obese pregnant women tended to be younger and lower 
ǡ      Ǥ     
             
gain during pregnancy, compared to normal weight women. Correlations between 
all fatty acid concentrations are shown in Supplementary Table S2.1.1. 
Ǧ   
in Supplementary Tables S2.1.2. Table S2.1.3  shows characteristics of women 






Saturated and monounsaturated fatty acid concentrations
Table 2.1.2    ͳǦ     ͲǤͲ͹
 ȏͻͷΨϐ  ȋȌǣͲǤͲͶǡͲǤͳͲȐ 	ǡ
ϐǡ
myristic acid concentrations (all P values<0.05). As compared to normal weight 
women, overweight and obese women had higher total SFA concentrations (all P val-
δͲǤͲͷȌǤͳǦͲǤͲͻȋͻͷΨ
ǣͲǤͲͷǡͲǤͳ͵Ȍ	ǡϐǡ
palmitic and stearic acid concentrations. Total saturated fatty acid concentrations 


















Age (years) 29.8 (5.2) 29.2 (5.3) 30.1 (5.2) 29.8 (5.2) 29.2 (5.0) <0.01
ȋȌ 167.6 (7.3) 168.7 (7.0) 167.9 (7.3) 166.3 (7.5) 165.7 (7.4) <0.01
ȋȌ 69.2 (13.1) 56.9 (6.7) 65.7 (7.3) 77.5 (8.6) 95.2 (13.8) <0.01
ȋȀ2) 23.7 (4.4) 18.9 (0.9) 22.2 (1.4) 26.9 (1.4) 33.9 (3.7) <0.01
ǡǤ
ȋΨȌ
2340 (42.9) 389 (45.3) 1508 (48.9) 360 (34.5) 83 (17.8) <0.01
ȀǡǤ
ȋΨȌ
3259 (58.4) 544 (62.2) 1976 (63.0) 529 (49.1) 210 (42.9) <0.01
ǡǤȋΨȌ 3230 (57.3) 563 (63.9) 1917 (60.7) 534 (48.8) 216 (43.3) <0.01
Total energy intake (kcal) 2013 (587) 2061 (606) 2040 (574) 1953 (588) 1878 (602) <0.01
ǡȋΨȌ 49.1 (6.6) 49.3 (6.9) 49.3 (6.5) 48.8 (6.6) 48.1 (7.2) 0.06
ǡȋΨȌ 14.9 (2.7) 14.6 (2.8) 14.9 (2.6) 15.0 (2.7) 15.2 (3.1) 0.03
	ǡΨ 35.8 (5.7) 35.9 (5.9) 35.6 (5.5) 36.0 (5.6) 36.6 (6.5) 0.07
Folic acid supplement use 
ȋȌǡǤȋΨȌ
3354 (72.0) 535 (74.5) 1990 (66.9) 596 (66.0) 233 (68.6) <0.01
Smoking during pregnancy 
ȋȌǡǤȋΨȌ
1442 (26.7) 249 (29.4) 778 (25.6) 279 (26.9) 136 (28.5) 0.03
Alcohol consumption 
during pregnancy (yes), 
ǤȋΨȌ
2785 (51.8) 478 (56.4) 1713 (56.5) 427 (41.6) 167 (35.5) <0.01
Gestational weight gain 
(kg)
14.9 (5.7) 14.9 (5.0) 15.4 (5.1) 14.3 (6.4) 11.7 (8.1) <0.01
Gestational weight gain 
categories
 ϐǡȋΨȌ 546 (20.2) 93 (21.2) 355 (21.6) 62 (13.6) 36 (22.8) <0.01
 ϐǡȋΨȌ 922 (34.2) 198 (45.1) 618 (37.6) 76 (16.7) 30 (19.0)
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N-3 and n-6 polyunsaturated fatty acid concentrations
Table 2.1.4 Ǧ͵
	    ǡ     
a-linolenic acid and eicosapentaenoic acid concentrations (all P values<0.05). As 
compared to normal weight women, underweight women tended to have lower 
Table 2.1.2.  Maternal weight during pregnancy with saturated fatty acid concentrations (N = 5,636)
ȋ	ȌȋͻͷΨϐȌ
Total SFAs (SD) Myristic acid (SD) Palmitic acid (SD) Stearic acid (SD)
Body mass indexa
ȏδʹͲǤͲȀ2Ȑ -0.18 (-0.25, -0.10)* -0.03 (-0.10, 0.04) -0.17 (-0.25, -0.10)* -0.16 (-0.24, -0.09)*
ȏʹͲǤͲǦʹͶǤͻȀ2Ȑ Reference Reference Reference Reference
ȏʹͷǤͲǦʹͻǤͻȀ2Ȑ 0.08 (0.01, 0.14)* -0.13 (-0.19, -0.06)* 0.08 (0.01, 0.15)* 0.08 (0.02, 0.15)*
ȏη͵ͲǤͲȀ2Ȑ 0.10 (0.00, 0.19)* -0.27 (-0.37, -0.18)* 0.13 (0.03, 0.22)* 0.07 (-0.03, 0.16)
ȋȌ 0.07 (0.04, 0.10)* -0.08 (-0.11, -0.06)* 0.08 (0.05, 0.11)* 0.06 (0.04. 0.09)*
ȋ	ȌȋͻͷΨϐȌ




-0.06 (-0.16, 0.05) -0.27 (-0.37, -0.17)* -0.04 (-0.14, 0.06) -0.06 (-0.16, 0.05)
ϐ Reference Reference Reference Reference
 0.16 (0.08, 0.25)* 0.15 (0.07, 0.23)* 0.15 (0.06, 0.23)* 0.17 (0.09, 0.26)*
Gestational weight gain (SD)c 0.09 (0.05, 0.13)* 0.18 (0.14, 0.22)* 0.08 (0.04, 0.11)* 0.10 (0.06, 0.14)*
Gestational weight gain (SD)d 0.10 (0.06, 0.14)* 0.17 (0.13, 0.21)* 0.09 (0.05, 0.12)* 0.11 (0.07, 0.15)*
aϐȋͻͷΨϐȌϐ
underweight, overweight and obese women as compared to normal weight women, and per SD increase in pre-pregnancy body mass 
Ǥǡǡǡǡǡ















concentrations, but was associated with higher a-linolenic acid eicosapentaenoic 
Ǥ Ǧ͵	
ϐǤ
Table 2.1.3.  Maternal weight during pregnancy with monounsaturated fatty acid concentrations (N = 
5,636)
Difference in monounsaturated fatty acids (MUFAs) concentrations 
ȋͻͷΨϐȌ
Total MUFAs (SD) Palmitoleic acid (SD) Oleic acid (SD)
Body mass indexa
ȏδʹͲǤͲȀ2Ȑ -0.05 (-0.12, 0.02) -0.12 (-0.19, -0.05)* -0.03 (-0.10, 0.04)
ȏʹͲǤͲǦʹͶǤͻȀ2Ȑ Reference Reference Reference
ȏʹͷǤͲǦʹͻǤͻȀ2Ȑ -0.02 (-0.08, 0.05) 0.06 (-0.01, 0.13) -0.03 (-0.10, 0.04)
ȏη͵ͲǤͲȀ2Ȑ -0.02 (-0.11, 0.07) 0.22 (0.13, 0.32)* -0.07 (-0.16, 0.02)
ȋȌ 0 (-0.02, 0.03) 0.08 (0.06, 0.11)* -0.01 (-0.04, 0.01)
Difference in monounsaturated fatty acids (MUFAs) concentrations 
ȋͻͷΨϐȌ
Total MUFAs (SD) Palmitoleic acid (SD) Oleic acid (SD)
Gestational weight gainb
ϐ -0.04 (-0.14, 0.06) -0.12 (-0.22, -0.01)* -0.04 (-0.14, 0.06)
ϐ Reference Reference Reference
 0.16 (0.08, 0.24)* 0.18 (0.10, 0.27)* 0.17 (0.08, 0.24)*
Gestational weight gain (SD)c 0.10 (0.06, 0.13)* 0.13 (0.10, 0.17)* 0.10 (0.06, 0.14)*
Gestational weight gain (SD)d 0.10 (0.06, 0.14)* 0.15 (0.11, 0.19)* 0.10 (0.06, 0.14)*
a   ϐ ȋͻͷΨ ϐ Ȍ  ϐ        
concentrations for underweight, overweight and obese women as compared to normal weight women, and per SD increase in pre-
Ǥǡǡǡǡǡ
acid supplement use and total caloric and fat intake during pregnancy.  bϐȋͻͷΨϐȌ
ϐϐ
ϐǡǤǡ






Table 2.1.5 ͳǦ ͲǤͲ͸
ȋͻͷΨ ǣ Ͳǡ ͲǤͲͻȌ   Ǧ͸ 	ǡ  ϐ   ǦɀǦ
ǡȋ
values<0.05). Compared to normal weight women, obese women had lower linoleic 
ǡǦɀǦ-
tions (all P values<0.05). A 1-SD higher gestational weight gain was associated with 
ͲǤͲͶ  ȋͻͷΨ ǣ ͲǤͲͳǡ ͲǤͲͺȌ   Ǧ͸ 	  ϐ  
ǦɀǦ  Ǥ      ϐ
ǡǦ͸	ȋP 
δͲǤͲͷȌǤ 
weight and obese women.
Table 2.1.4.  Maternal weight during pregnancy with n-3 polyunsaturated fatty acid concentrations (N = 
5,636)
Difference in n-3 Polyunsaturated fatty acids (PUFAs) concentrations
ȋͻͷΨϐȌ






ȏδʹͲǤͲȀ2Ȑ -0.11 (-0.18, -0.05)* 0.06 (-0.01, 0.13) -0.03 (-0.10, 0.04) -0.13 (-0.20, -0.06)*
ȏʹͲǤͲǦʹͶǤͻȀ2Ȑ Reference Reference Reference Reference
ȏʹͷǤͲǦʹͻǤͻȀ2Ȑ -0.04 (-0.11, 0.02) -0.17 (-0.24, -0.11)* -0.05 (-0.11, 0.02) -0.01 (-0.07, 0.06)
ȏη͵ͲǤͲȀ2Ȑ -0.11 (-0.20, -0.02)* -0.32 (-0.41, -0.23)* -0.10 (-0.19, -0.01)* -0.05 (-0.14, 0.04)
ȋȌ -0.02 (-0.04, 0.01) -0.12 (-0.15, -0.09)* -0.03 (-0.05, -0.01)* 0.01 (-0.02, 0.03)
Difference in n-3 Polyunsaturated fatty acids (PUFAs) concentrations
ȋͻͷΨϐȌ







ϐ -0.07 (-0.17, 0.03) -0.14 (-0.24, -0.04)* -0.18 (-0.28, -0.07)* -0.01 (-0.11, 0.09)
ϐ Reference Reference Reference Reference
 0.01 (-0.08, 0.09) 0.05 (-0.03, 0.14) 0.02 (-0.07, 0.11) -0.02 (-0.11, 0.06)
Gestational weight gain (SD)c 0.03 (-0.01, 0.06) 0.09 (0.05, 0.13)* 0.08 (0.04, 0.12)* -0.02 (-0.06, 0.02)
Gestational weight gain (SD)d 0.02 (-0.02, 0.06) 0.07 (0.04, 0.11)* 0.08 (0.04, 0.12)* -0.02 (-0.06, 0.02)
a   ϐ ȋͻͷΨ ϐ Ȍ  ϐ      Ǧ͵ 	  
underweight, overweight and obese women as compared to normal weight women, and per SD increase in pre-pregnancy body mass 
Ǥǡǡǡǡǡǡ













Figure 2.1.2  shows that as compared to normal weight women, those with obesity 
ͲǤͲ͹ȋͻͷΨǣǦͲǤͲʹǡͲǤͳͷȌǦ͸ȀǦ͵	Ǥǡ
  ϐǡ 
ͲǤͲ͸ȋͻͷΨǣǦͲǤͲͳǡͲǤͳͶȌǦ͸ȀǦ͵	Ǥ










ȏδʹͲǤͲȀ2Ȑ -0.17 (-0.24, -0.09)* -0.03 (-0.11, 0.04) -0.27 (-0.34, -0.20)* -0.23 (-0.30, -0.16)*
ȏʹͲǤͲǦʹͶǤͻȀ2Ȑ Reference Reference Reference Reference
ȏʹͷǤͲǦʹͻǤͻȀ2Ȑ 0.09 (0.02, 0.16)* -0.03 (-0.09, 0.04) 0.16 (0.10, 0.23)* 0.23 (0.16, 0.30)*
ȏη͵ͲǤͲȀ2Ȑ 0.06 (-0.04, 0.15) -0.23 (-0.32, -0.13)* 0.35 (0.26, 0.45)* 0.45 (0.35, 0.54)*
ȋȌ 0.06 (0, 0.09)* -0.05 (-0.08, -0.02)* 0.16 (0.14, 0.19)* 0.19 (0.17, 0.22)*
Ǧ͸ȋ	ȌȋͻͷΨϐ
Interval)







ϐ 0.02 (-0.08, 0.12) 0.02 (-0.09, 0.12) -0.08 (-0.18, 0.02) 0.07 (-0.04, 0.17)
ϐ Reference Reference Reference Reference
 0.12 (0.04, 0.21)* 0.05 (-0.04, 0.13) 0.29 (0.21, 0.37)* 0.05 (-0.03, 0.13)
Gestational weight gain (SD)c 0.04 (0.01, 0.08)* 0.02 (-0.02, 0.06) 0.15 (0.11, 0.19)* -0.03 (-0.06, 0.01)
Gestational weight gain (SD)d 0.05 (0.02, 0.09)* 0.01 (-0.02, 0.05) 0.18 (0.14, 0.22)* -0.00 (-0.04, 0.04)
a   ϐ ȋͻͷΨ ϐ Ȍ  ϐ      Ǧ͸ 	  
underweight, overweight and obese women as compared to normal weight women, and per SD increase in pre-pregnancy body mass 
Ǥǡǡǡǡǡ













tary Tables S2.1.4 and S2.1.5ȌǤ
ȋSupplementary Tables S2.1.6–S2.1.9). 
         Supplementary Tables 
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In this population-based cohort study, we observed that higher prepregnancy body 
	Ǧ͸	Ǥ




This study was embedded in a population-based prospective cohort with a large 





these measurements restricts us for drawing conclusions about the direction of any 
Ǥǡ
high degree of tracking over time.34,35 Information on maternal prepregnancy weight 
  ǦǤ    
ǡ
ǡǦǤ
number of fatty acid concentrations in plasma samples only once during pregnancy. 
No information was available about fatty acid concentrations in other trimesters. 
	    ϐ        -
ʹ36. 
ǡ       ǡ 
 ϐ    Ǥ    
ϐȋ		Ȍ-
ses for maternal total energy and fat intake. No differences in results were observed 
        Ǥ ǡ 
		   Ǥ	
          

Ǥǡ-





are associated with adverse maternal and neonatal outcomes.9,37 Multiple previous 
          
gestational weight gain are associated with increased risks of gestational diabetes, 
neonatal mortality, and obesity in offspring.11,12,15,37-39 The mechanism linking higher 
         
may include fetal overnutrition.16	
fatty acids may lead to intrauterine metabolic adaptations and disproportionate 
fetal growth.40 Increased concentrations of free fatty acids during pregnancy are as-
sociated with childhood obesity.41,42ǡ
Ǧ͵	Ǧ͸	
lower childhood systolic blood pressure.43 
Results from previous studies support associations of obesity with fatty acid con-
ǤͳʹͶ
Ǧ͵	Ǥ19 A systematic review based on 21 studies 
showed that overweight or obese adults had lower linoleic acid and higher dihomo-
ɀǦǡǦ͸	Ǥ44 A study among 120 adolescents aged 12 years old from 
France showed that overweight adolescents had higher SFA concentrations and lower 
 Ǧ͵ 	 Ǥ45        
Ǥ20 This study 
ͳʹͻǡ
    ǡ  Ǧ͵ 	ǡ  ǡ 
Ǧ͸	ǡǤ20 No information about other fatty acid 
concentrations was available. In line with these previous results, we observed that 
Ǧ͸	Ǥ
ǡǦɀǦ
   Ǥ  Ǧ͵ 	    
ȽǦǤ	
the SFAs, obese women had lower myristic acid concentrations and higher palmitic 
ǡ  	ǡ
Ǥ






















       ǡ    
ϐǤ

        ϐǡ  




tions lead to higher adipose tissue development through promotion of preadipocyte 
    Ǧ͵ 	    
mass and suppresses development of obesity.46,47 Also, saturated fatty acids and the 
monounsaturated fatty acids stimulate adipocyte differentiation and triacylglycerol 
accumulation.48 In the other direction, obesity alters adipose tissue metabolic and 
endocrine function and leads to an increased release of fatty acids, affecting sub-
       Ǥ49 Further studies are needed 
         Ǥ  
longitudinal measurements of both weight and fatty acid concentrations before 
and during pregnancy may help to identify the direction of these associations. Also, 
































































































  ǣ   
Ǥ ǣ














 ʹͺǤ  ǡ  ǡ  ǡ  ǡ  Ǥ      
composition and dietary fat intake in women with gestational diabetes mellitus or mild gestational 
ǤʹͲͳͲǢ͵͵ȋͻȌǣʹͲͶͻǦʹͲͷͶǤ






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Age (years) 29.3 (5.6) 30.7 (5.2) 31.5 (4.4) 30.8 (4.7) 0.02
ȋȌ 169.0 (7.2) 167.8 (6.9) 168.9 (7.3) 169.7 (7.1) <0.01
ȋȌ 68.7 (12.1) 65.6 (11.9) 65.6 (10.4) 72.5 (12.6) <0.01
ȋȀ2) 23.2 (3.9) 23.1 (4.3) 22.2 (3.2) 23.9 (4.0) <0.01
ǡǤȋΨȌ 1541 (57.9) 284 (52.8) 583 (64.2) 674 (55.5) <0.01
ȀǡǤȋΨȌ 1939 (72.2) 352 (64.7) 680 (74) 907 (74) <0.01
ǡǤȋΨȌ 1635 (60.7) 292 (53.5) 534 (57.9) 809 (65.9) <0.01
Total energy intake (kcal) 2079 (543) 2066 (567) 2043 (554) 2110 (523) 0.56
ǡȋΨȌ 48.5 (6.2) 48.9 (6.1) 48.1 (6.3) 48.6 (6.2) 0.36
ǡȋΨȌ 15.1 (2.6) 15.2 (2.6) 15.2 (2.5) 14.9 (2.6) 0.49
	ǡȋΨȌ 36.0 (5.3) 35.5 (5.4) 36.2 (5.3) 36.1 (5.3) 0.38
Folic acid supplement use (yes), No. 
ȋΨȌ
1919 (83.6) 360 (77.7) 656 (84.7) 903 (85.2) <0.01
Smoking during pregnancy (yes), 
ǤȋΨȌ
614 (23.8) 80 (15.2) 170 (19.3) 364 (30.9) <0.01
Alcohol consumption during 
ȋȌǡǤȋΨȌ
1598 (61.9) 310 (58.8) 581 (65.9) 707 (60.3) 0.02
aȋȌǡȋͻͷΨȌǡȋΨȌǤȗ
ͳǦǤ
Table S2.1.4.  Associations of maternal gestational weight gain during pregnancy with saturated and 
ȋαʹǡ͸ͻ͹Ȍa
Difference in saturated fatty acid (SFA) concentrations  
ȋͻͷΨϐȌ
Total SFAs (SD) Myristic acid (SD) Palmitic acid (SD) Stearic acid (SD)
Gestational weight gainb,c
ϐ -0.05 (-0.15, 0.06) -0.28 (-0.38, -0.18)* -0.03 (-0.13, 0.07) -0.05 (-0.15, 0.06)
ϐ Reference Reference Reference Reference
 0.19 (0.10, 0.27)* 0.11 (0.03, 0.19)* 0.17 (0.09, 0.25)* 0.20 (0.11, 0.28)*
Difference in monounsaturated fatty acids (MUFAs) concentrations  
ȋͻͷΨϐȌ
Total MUFAs (SD) Palmitoleic acid (SD) Oleic acid (SD)
Gestational weight gainb,c
ϐ -0.04 (-0.14, 0.06) -0.10 (-0.20, 0) -0.05 (-0.15, 0.05)
ϐ Reference Reference Reference










Table S2.1.5.  Associations of maternal gestational weight gain during pregnancy with n-3 and n-6 
ȋαʹǡ͸ͻ͹Ȍa
Difference in n-3 Polyunsaturated fatty acids (PUFAs) concentrations 
ȋͻͷΨϐȌ




ϐ -0.07 (-0.18, 0.03) -0.16 (-0.26, -0.06)* -0.18 (-0.29, -0.08)* -0.01 (-0.11, 0.09)
ϐ Reference Reference Reference Reference
 -0.01 (-0.09, 0.07) -0.01 (-0.09, 0.08) -0.01 (-0.09, 0.09) -0.03 (-0.11, 0.06)
Difference in n-6 Polyunsaturated fatty acids (PUFAs) concentrations 
ȋͻͷΨϐȌ
Total n-6 PUFAs (SD)
ȋȌ
Dihomo-gamma 
linolenic acid (SD) Arachidonic acid (SD)
Gestational weight gainb,c
ϐ 0.03 (-0.07, 0.13) 0.01 (-0.10, 0.11) -0.05 (-0.15, 0.05) 0.10 (-0.02, 0.20)
ϐ Reference Reference Reference Reference
 0.15 (0.07, 0.23)* 0.03 (-0.06, 0.11) 0.36 (0.28, 0.44)* 0.13 (0.04, 0.22)*
aϐȋͻͷΨϐȌϐǦ͵Ǧ͸	
ϐϐǤb
maternal age, educational level, ethnicity, parity, smoking and alcohol consumption, folic acid supplement use and total caloric and fat 
intake during pregnancy. cǤȗǦδͲǤͲͷ
Table S2.1.6.  Associations of maternal weight during pregnancy with saturated fatty acid concentrations 
ȋαͷǡ͸͵͸Ȍa,b
ȋ	ȌȋͻͷΨϐȌ
Total SFAs (SD) Myristic acid (SD) Palmitic acid (SD) Stearic acid (SD)
Body mass indexc
ȏδʹͲǤͲȀ2Ȑ -0.17 (-0.24, -0.10)* -0.03 (-0.10, 0.05) -0.17 (-0.24, -0.10)* -0.16 (-0.23, -0.09)*
ȏʹͲǤͲǦʹͶǤͻȀ2Ȑ Reference Reference Reference Reference
ȏʹͷǤͲǦʹͻǤͻȀ2Ȑ 0.07 (0.01, 0.14)* -0.13 (-0.20, -0.07)* 0.07 (0.01, 0.14)* 0.08 (0.02, 0.15)*
ȏη͵ͲǤͲȀ2Ȑ 0.08 (-0.01, 0.18) -0.29 (-0.38, -0.20)* 0.11 (0.01, 0.20)* 0.06 (-0.04, 0.15)
ȋȌ 0.07 (0.04, 0.09)* -0.09 (-0.11, -0.06)* 0.07 (0.05, 0.10)* 0.06 (0.03, 0.09)*
ȋ	ȌȋͻͷΨϐȌ
Total SFAs (SD) Myristic acid (SD) Palmitic acid (SD) Stearic acid (SD)
Gestational weight gainc
ϐ -0.06 (-0.16, 0.05) -0.26 (-0.36, -0.16)* -0.04 (-0.14, 0.06) -0.06 (-0.16, 0.05)
ϐ Reference Reference Reference Reference
 0.16 (0.08, 0.25)* 0.15 (0.07, 0.23)* 0.15 (0.06, 0.23)* 0.18 (0.09, 0.26)*
Gestational weight gain (SD)d 0.09 (0.05, 0.13)* 0.18 (0.14, 0.22)* 0.08 (0.04, 0.11)* 0.10 (0.06, 0.14)*
Gestational weight gain (SD)e 0.10 (0.06, 0.14)* 0.17 (0.14, 0.21)* 0.09 (0.05, 0.12)* 0.11 (0.07, 0.15)*
aϐȋͻͷΨϐȌϐ












Table S2.1.7.  Associations of maternal weight during pregnancy with monounsaturated fatty acid 
ȋαͷǡ͸͵͸Ȍa,b
Difference in monounsaturated fatty acids (MUFAs) concentrations  
ȋͻͷΨϐȌ
Total MUFAs (SD) Palmitoleic acid (SD) Oleic acid (SD)
Body mass indexc
ȏδʹͲǤͲȀ2Ȑ -0.05 (-0.12, 0.02) -0.12 (-0.19, -0.05)* -0.02 (-0.09, 0.05)
ȏʹͲǤͲǦʹͶǤͻȀ2Ȑ Reference Reference Reference
ȏʹͷǤͲǦʹͻǤͻȀ2Ȑ -0.02 (-0.09, 0.04) 0.05 (-0.02, 0.12) -0.03 (-0.10, 0.03)
ȏη͵ͲǤͲȀ2Ȑ -0.04 (-0.13, 0.05) 0.21 (0.11, 0.30)* -0.09 (-0.18, 0.01)
ȋȌ
-0.01 (-0.03, 0.02) 0.08 (0.05, 0.10)* -0.02 (-0.05, 0.01)
Difference in monounsaturated fatty acids (MUFAs) concentrations  
ȋͻͷΨϐȌ
Total MUFAs (SD) Palmitoleic acid (SD) Oleic acid (SD)
Gestational weight gainc
ϐ -0.04 (-0.13, 0.06) -0.11 (-0.21, -0.01)* -0.04 (-0.14, 0.06)
ϐ Reference Reference Reference
 0.16 (0.08, 0.24)* 0.18 (0.10, 0.27)* 0.16 (0.08, 0.24)*
Gestational weight gain (SD)d 0.10 (0.06, 0.13)* 0.13 (0.10, 0.17)* 0.10 (0.06, 0.14)*
Gestational weight gain (SD)e 0.10 (0.06, 0.14)* 0.15 (0.11, 0.18)* 0.10 (0.06, 0.14)*
a   ϐ ȋͻͷΨ ϐ Ȍ  ϐ        
concentrations for underweight, overweight and obese women as compared to normal weight women, and per SD increase in pre-
Ǥǡǡǡǡ
acid supplement use during pregnancy. bϐȋͻͷΨϐȌϐ
ϐǡ
ϐǡǤǡǡǡǡ









Table S2.1.8.  Associations of maternal weight during pregnancy with n-3 polyunsaturated fatty acid 
ȋαͷǡ͸͵͸Ȍa,b
Difference in n-3 Polyunsaturated fatty acids (PUFAs) concentrations
ȋͻͷΨϐȌ






ȏδʹͲǤͲȀ2Ȑ -0.11 (-0.18, -0.05)* 0.06 (-0.01, 0.13) -0.03 (-0.10, 0.04) -0.13 (-0.20, -0.06)*
ȏʹͲǤͲǦʹͶǤͻȀ2Ȑ Reference Reference Reference Reference
ȏʹͷǤͲǦʹͻǤͻȀ2Ȑ -0.04 (-0.11, 0.02) -0.18 (-0.24, -0.11)* -0.05 (-0.11, 0.02) -0.01 (-0.07, 0.06)
ȏη͵ͲǤͲȀ2Ȑ -0.10 (-0.19, -0.02)* -0.34 (-0.43, -0.25)* -0.09 (-0.18, 0.01) -0.04 (-0.13, 0.05)
ȋȌ -0.02 (-0.04, 0.01) -0.13 (-0.15, -0.10)* -0.02 (-0.05, 0.01) 0.01 (-0.02, 0.03)
Difference in n-3 Polyunsaturated fatty acids (PUFAs) concentrations
ȋͻͷΨϐȌ






ϐ -0.07 (-0.17, 0.04) -0.14 (-0.24, -0.04)* -0.18 (-0.28, -0.07)* -0.01 (-0.11, 0.10)
ϐ Reference Reference Reference Reference
 0.01 (-0.08, 0.09) 0.05 (-0.03, 0.14) 0.02 (-0.07, 0.11) -0.02 (-0.11, 0.06)
Gestational weight gain (SD)d 0.03 (-0.01, 0.06) 0.09 (0.05, 0.13)* 0.08 (0.04, 0.12)* -0.02 (-0.06, 0.02)
Gestational weight gain (SD)e 0.02 (-0.02, 0.06) 0.07 (0.04, 0.11)* 0.08 (0.04, 0.12)* -0.02 (-0.06, 0.02)
a   ϐ ȋͻͷΨ ϐ Ȍ  ϐ      Ǧ͵ 	  
underweight, overweight and obese women as compared to normal weight women, and per SD increase in pre-pregnancy body mass 
Ǥǡǡǡǡǡ









Table S2.1.9.  Associations of maternal weight during pregnancy with n-6 polyunsaturated fatty acid 
ȋαͷǡ͸͵͸Ȍa,b
Difference in n-6 Polyunsaturated fatty acids (PUFAs) concentrations 
ȋͻͷΨϐȌ






ȏδʹͲǤͲȀ2Ȑ -0.16 (-0.24, -0.09)* -0.03 (-0.10, 0.04) -0.27 (-0.34, -0.20)* -0.23 (-0.30, -0.16)*
ȏʹͲǤͲǦʹͶǤͻȀ2Ȑ Reference Reference Reference Reference
ȏʹͷǤͲǦʹͻǤͻȀ2Ȑ 0.09 (0.02, 0.16)* -0.02 (-0.09, 0.05) 0.16 (0.09, 0.23)* 0.23 (0.16, 0.30)*
ȏη͵ͲǤͲȀ2Ȑ 0.05 (-0.05, 0.14) -0.23 (-0.32, -0.13)* 0.34 (0.24, 0.43)* 0.44 (0.34, 0.53)*
ȋȌ 0.06 (0.03, 0.09)* -0.05 (-0.08, -0.02)* 0.16 (0.13, 0.18)* 0.19 (0.16, 0.22)*
Difference in n-6 Polyunsaturated fatty acids (PUFAs) concentrations 
ȋͻͷΨϐȌ








ϐ 0.02 (-0.09, 0.12) 0.01 (-0.09, 0.11) -0.08 (-0.18, 0.02) 0.07 (-0.03, 0.17)
ϐ Reference Reference Reference Reference
 0.13 (0.04, 0.21)* 0.05 (-0.04, 0.14) 0.29 (0.21, 0.38)* 0.05 (-0.03, 0.13)
Gestational weight gain (SD)d 0.04 (0.01, 0.08)* 0.02 (-0.02, 0.06) 0.15 (0.11, 0.19)* -0.03 (-0.06, 0.01)
Gestational weight gain (SD)e 0.05 (0.02, 0.09)* 0.01 (-0.02, 0.05) 0.18 (0.14, 0.22)* -0.00 (-0.04, 0.04)
a   ϐ ȋͻͷΨ ϐ Ȍ  ϐ      Ǧ͸ 	  
underweight, overweight and obese women as compared to normal weight women, and per SD increase in pre-pregnancy body mass 
Ǥǡǡǡǡǡ
use during pregnancy. b   ϐ ȋͻͷΨϐ Ȍ  ϐ    Ǧ͸	
ϐǡϐǡ
Ǥǡǡǡǡǡ
alcohol consumption and folic acid supplement use during pregnancy. cǤ








Table S2.1.10.  Associations of maternal weight during pregnancy with saturated fatty acid concentrations 
ȋαͷǡ͸͵͸Ȍa,b
ȋ	ȌȋͻͷΨϐȌ
Total SFAs (SD) Myristic acid (SD) Palmitic acid (SD) Stearic acid (SD)
Body mass indexc
ȏδʹͲǤͲȀ2Ȑ -0.20 (-0.28, -0.13)* -0.05 (-0.12, 0.02) -0.20 (-0.28, -0.13)* -0.18 (-0.25, -0.10)*
ȏʹͲǤͲǦʹͶǤͻȀ2Ȑ Reference Reference Reference Reference
ȏʹͷǤͲǦʹͻǤͻȀ2Ȑ 0.04 (-0.03, 0.11)* -0.19 (-0.26, -0.12)* 0.03 (-0.04, 0.10) 0.09 (0.02, 0.16)*
ȏη͵ͲǤͲȀ2Ȑ 0.03 (-0.06, 0.12)* -0.39 (-0.48, -0.29)* 0.03 (-0.06, 0.13) 0.07 (-0.03, 0.16)
ȋȌ 0.06 (0.03, 0.08)* -0.11 (-0.14, -0.09)* 0.06 (0.03, 0.08)* 0.07 (0.04. 0.09)*
ȋ	ȌȋͻͷΨϐȌ
Total SFAs (SD) Myristic acid (SD) Palmitic acid (SD) Stearic acid (SD)
Gestational weight gainc
ϐ -0.08 (-0.18, 0.02) -0.30 (-0.40, -0.20)* -0.07 (-0.17, 0.03) -0.06 (-0.16, 0.04)
ϐ Reference Reference Reference Reference
 0.17 (0.09, 0.25)* 0.16 (0.08, 0.24)* 0.15 (0.07, 0.23)* 0.19 (0.10, 0.27)*
Gestational weight gain (SD)d 0.09 (0.05, 0.13)* 0.18 (0.14, 0.22)* 0.08 (0.04, 0.11)* 0.10 (0.06, 0.14)*
Gestational weight gain (SD)e 0.10 (0.06, 0.14)* 0.17 (0.13, 0.21)* 0.09 (0.05, 0.12)* 0.11 (0.07, 0.15)*
aϐȋͻͷΨϐȌϐ
for underweight, overweight and obese women as compared to normal weight women, and per SD increase in pre-pregnancy body 
 Ǥ b   ϐ ȋͻͷΨϐ Ȍ  ϐ        
ϐϐǡ






Table S2.1.11.  Associations of maternal weight during pregnancy with monounsaturated fatty acid 
ȋαͷǡ͸͵͸Ȍa,b
Difference in monounsaturated fatty acids (MUFAs) concentrations  
ȋͻͷΨϐȌ
Total MUFAs (SD) Palmitoleic acid (SD) Oleic acid (SD)
Body mass indexc
ȏδʹͲǤͲȀ2Ȑ -0.06 (-0.14, 0.01) -0.12 (-0.19, -0.05)* -0.05 (-0.12, 0.03)
ȏʹͲǤͲǦʹͶǤͻȀ2Ȑ Reference Reference Reference
ȏʹͷǤͲǦʹͻǤͻȀ2Ȑ -0.14 (-0.20, -0.07)* -0.02 (-0.09, 0.05) -0.15 (-0.22, -0.08)*
ȏη͵ͲǤͲȀ2Ȑ -0.22 (-0.31, -0.12)* 0.11 (0.01, 0.20)* -0.26 (-0.36, -0.17)*
ȋȌ -0.06 (-0.08, -0.03)* 0.05 (0.02, 0.07)* -0.07 (-0.10, -0.05)*
Difference in monounsaturated fatty acids (MUFAs) concentrations 
ȋͻͷΨϐȌ
Total MUFAs (SD) Palmitoleic acid (SD) Oleic acid (SD)
Gestational weight gainc
ϐ -0.10 (-0.20, 0) -0.15 (-0.25, -0.05)* -0.10 (-0.20, 0)
ϐ Reference Reference Reference
 0.17 (0.09, 0.26)* 0.22 (0.14, 0.31)* 0.17 (0.09, 0.25)*
Gestational weight gain (SD)d 0.10 (0.06, 0.13)* 0.13 (0.10, 0.17)* 0.10 (0.06, 0.14)*
Gestational weight gain (SD)e 0.10 (0.06, 0.14)* 0.15 (0.11, 0.19)* 0.10 (0.06, 0.14)*
a   ϐ ȋͻͷΨ ϐ Ȍ  ϐ        
concentrations for underweight, overweight and obese women as compared to normal weight women, and per SD increase in 
  Ǥ b   ϐ ȋͻͷΨϐ Ȍ  ϐ     
     ϐ     
ϐǡǤcǤ








Table S2.1.12.  Associations of maternal weight during pregnancy with n-3 polyunsaturated fatty acid 
ȋαͷǡ͸͵͸Ȍa
Difference in n-3 Polyunsaturated fatty acids (PUFAs) concentrations 
ȋͻͷΨϐȌ




ȏδʹͲǤͲȀ2Ȑ -0.16 (-0.24, -0.09)* 0.04 (-0.03, 0.12) -0.07 (-0.15, 0.01) -0.18 (-0.26, -0.11)*
ȏʹͲǤͲǦʹͶǤͻȀ2Ȑ Reference Reference Reference Reference
ȏʹͷǤͲǦʹͻǤͻȀ2Ȑ -0.16 (-0.23, -0.09)* -0.25 (-0.32, -0.18)* -0.17 (-0.23, -0.10)* -0.13 (-0.19, -0.06)*
ȏη͵ͲǤͲȀ2Ȑ -0.32 (-0.41, -0.22)* -0.44 (-0.54, -0.35)* -0.30 (-0.40, -0.21)* -0.26 (-0.36, -0.17)*
ȋȌ -0.07 (-0.10, -0.05)* -0.16 (-0.18, -0.13)* -0.08 (-0.11, -0.06)* -0.05 (-0.08, -0.02)*
Difference in n-3 Polyunsaturated fatty acids (PUFAs) concentrations 
ȋͻͷΨϐȌ




ϐ -0.15 (-0.25, -0.04)* -0.18 (-0.28, -0.07)* -0.25 (-0.36, -0.14)* -0.08 (-0.19, 0.03)
ϐ Reference Reference Reference Reference
 -0.01 (-0.10, 0.08) 0.07 (-0.01, 0.15) 0.01 (-0.08, 0.10) -0.04 (-0.13, 0.05)
Gestational weight gain (SD)d 0.03 (-0.01, 0.06) 0.09 (0.05, 0.13)* 0.08 (0.04, 0.12)* -0.02 (-0.06, 0.02)
Gestational weight gain (SD)e 0.02 (-0.02, 0.06) 0.07 (0.04, 0.11)* 0.08 (0.04, 0.12)* -0.02 (-0.06, 0.02)
a   ϐ ȋͻͷΨ ϐ Ȍ  ϐ      Ǧ͵ 	  
underweight, overweight and obese women as compared to normal weight women, and per SD increase in pre-pregnancy body mass 
ǤbϐȋͻͷΨϐȌϐǦ͵	
ϐǡϐǡ





Table S2.1.13.  Associations of maternal weight during pregnancy with n-6 polyunsaturated fatty acid 
ȋαͷǡ͸͵͸Ȍa,b
Difference in n-6 Polyunsaturated fatty acids (PUFAs) concentrations  
ȋͻͷΨϐȌ






ȏδʹͲǤͲȀ2Ȑ -0.18 (-0.26, -0.11)* -0.04 (-0.12, 0.03) -0.28 (-0.36, -0.21)* -0.25 (-0.32, -0.17)*
ȏʹͲǤͲǦʹͶǤͻȀ2Ȑ Reference Reference Reference Reference
ȏʹͷǤͲǦʹͻǤͻȀ2Ȑ 0.16 (0.10, 0.23)* 0.05 (-0.02, 0.11) 0.12 (0.05, 0.19)* 0.28 (0.21, 0.34)*
ȏη͵ͲǤͲȀ2Ȑ 0.15 (0.06, 0.25)* -0.13 (-0.22, -0.04)* 0.28 (0.18, 0.37)* 0.51 (0.42, 0.60)*
ȋȌ 0.10 (0.08, 0.13)* -0.01 (-0.04, 0.01) 0.14 (0.12, 0.17)* 0.22 (0.19, 0.24)*
Difference in n-6 Polyunsaturated fatty acids (PUFAs) concentrations  
ȋͻͷΨϐȌ






ϐ 0.05 (-0.06, 0.15) 0.05 (-0.06, 0.15) -0.10 (-0.19, 0.01) 0.08 (-0.02, 0.18)
ϐ Reference Reference Reference Reference
 0.13 (0.04, 0.21)* 0.05 (-0.04, 0.13) 0.31 (0.23, 0.39)* 0.06 (-0.03, 0.14)
Gestational weight gain (SD)d 0.04 (0.01, 0.08)* 0.02 (-0.02, 0.06) 0.15 (0.11, 0.19)* -0.03 (-0.06, 0.01)
Gestational weight gain (SD)e 0.05 (0.02, 0.09)* 0.01 (-0.02, 0.05) 0.18 (0.14, 0.22)* -0.00 (-0.04, 0.04)
a   ϐ ȋͻͷΨ ϐ Ȍ  ϐ      Ǧ͸ 	  










Fatty acids and hemodynamic 
adaptations during pregnancy 
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 Ǥ       
affects blood pressure development, placental vascular resistance and the risk of 
gestational hypertensive disorders. 
Methods and Results: This study was embedded in a population-based prospective 
͸ǡͺʹ͵Ǥȋ	Ȍǡ
ȋ	ȌǡǦ͵ȋǦ͵	Ȍ
Ǧ͸   ȋǦ͸	Ȍ    
ʹͲǤͷȋͻͷΨǣͳ͸ǤͷǡʹͶǤͻȌǤ
    Ǥ      
were assessed in the second and third trimester. Information about doctor diag-
      Ǥ
   	 ǡ  	 ǡ
      ϐ   ȋP val-
δͲǤͲͷȌǤǦ͵	Ǧ͸	ǡ
  ȋȌ    ȋȌǡ   
blood pressure throughout pregnancy (P values<0.05). Maternal fatty acid concen-




Conclusions:      ϐǡ   
		ǡ
maternal blood pressure levels throughout pregnancy, but not with placental vascu-
 Ǥ	ǡ ǡ-
ated with an increased risk of gestational hypertensive disorders. Further studies 
are needed to identify through which pathways different fatty acids affect maternal 






    ϐ        -
ease.1-3 Results from observational studies and randomized controlled trials suggest 
that higher saturated fatty acids (SFA) concentrations adversely affect cholesterol 
metabolism and are associated with increased risks of hypertension and coronary 
heart disease.1,4ǡǦ͵ȋ	Ȍ-
ǡȋȌǡǦ͸	ǡϐ
pressure levels and endothelial function.5-7 For the current study, we hypothesized 
    ϐǡ      	 
   	      
ǤǦ͵	
ǦǦϐ-
ǡ ϐ Ǥ8,9 Conversely, SFA 
      ϐ ǡ -
ϐϐ
in placental dysfunction.10,11 Abnormal placental development leads to pregnancy-
related hemodynamic maladaptions and gestational hypertensive disorders.12 Thus 
ǡǦ͵	
during pregnancy are associated with a lower risk of pre-eclampsia, whereas higher 
	Ǧ͸	Ǧ-
sia.13,14ǡǡ
     Ǥ13-16 In addition, not much is 
known about the direct associations of different fatty acid concentrations with blood 
pressure development during pregnancy and placental vascular function. 
Therefore, in a population based prospective cohort study from early pregnancy 
onwards among 6,823 pregnant women, we assessed the associations of maternal 
plasma fatty acid concentrations with longitudinal blood pressure development, 




This study was embedded in the Generation R Study, a population-based prospective 






whom 6,999 had information on mid-pregnancy fatty acid concentrations available. 
       Ǧ   

vascular function available, leading to a population for analysis of 6,823 pregnant 




and transported to the Division of Metabolic Diseases and Nutritional Medicine, Dr. 
 ǯ ǡ   Ǥ  
thawed, the analysis of plasma glycerophospholipid fatty acids was performed by a 
sensitive and precise high throughput method. This method is suitable for applica-
tions in large epidemiological studies.20ϐǡ
selected fatty acids for our analyses, which have been associated with the risk of 
cardiovascular disease in adults and adverse pregnancy outcomes.2,21-25 Selected sat-
urated fatty acids included total SFA concentrations, myristic acid (C14:0), palmitic 
acid (C16:0) and stearic acid (C18:0). Monounsaturated fatty acids included total 
	ǡȋͳ͸ǣͳ͹ȌȋͳͺǣͳͻȌǤ-
   Ǧ͵	ǡȽǦ ȋǡ






the relative importance of a fatty acids set against the total fatty acids concentra-
tions.26
Blood pressure measurements
       ͻͲ͹̺  
  ȋ   ǤǤ ǡ 
Netherlands).27 All pregnant women were seated in upright position with back sup-
ǡͷǤǦ







interval was documented for each participant. In total, we measured blood pressure 
ͷǡʹͶ͸ϐȋͳ͵ǤʹǡͻͷΨͻǤͷǡ
17.4), in 6,790 women in second trimester (median 20.4 weeks of gestation, range 
18.5-23.5), and in 6,469 women in third trimester (median 30.2 weeks of gestation, 
ͻͷΨʹͺǤ͸Ǧ͵ʹǤͺȌǤ	ǡͳͺǡͷͲͷ
available. 
Placental vascular resistance indices
ϐ
from the umbilical and uterine arteries in second and third trimester, as described 
previously.12




    Ǥ 	 ǡ  





suspected of pregnancy complications based on these records were crosschecked 
with the original hospital charts, as described elsewhere.30 ϐǡ  
criteria were used to identify women with gestational hypertension: development of 
ηͳͶͲȀηͻͲ-
ter 20 weeks of gestation in previously normotensive women. These criteria plus the 
ȋϐʹΪǡ
ͳΪǡʹͶ
least 300 mg of protein) were used to identify women with preeclampsia.31 Informa-




visit.17 Information on age was assessed at intake. Maternal weight and height were 
ǡǤ-






	ǡ        -
peatedly measured systolic and diastolic blood pressure using unbalanced repeated 
measurement regression models. These models take the correlation between re-
      ǡ    
outcome data.32 They are described in detail in the Supplementary Material. Second, 

diastolic blood pressure in each trimester of pregnancy, placental vascular function 
in the second and third trimester of pregnancy and with presence of third-trimester 
notching using regular multivariate linear and logistic regression models. Finally, 
we assessed the associations of maternal fatty acid concentrations with the risk of 
gestational hypertensive disorders using multivariate logistic regression models. 
The effect estimates for these associations are shown per standard deviation change 
in maternal fatty acid concentrations to enable comparison of effect estimates. All 
           
placental vascular resistance measurement, age, parity, ethnicity, educational level, 
ǡǡǡ-
tation use, and total calorie intake during pregnancy. These covariates were selected 
based on their associations with the outcomes of interest based on previous studies 
εͳͲΨǤ
multiple imputations. Five imputed dataset were created and analysed together. The 
repeated measurement analysis was performed using the Statistical Analysis System 
ͻǤʹȋǡǤ
ǡȌǡ





Characteristics of the participants are shown in Table 2.2.1.  Second trimester ma-
	ǡ	ǡǦ͵Ǧ͸	͸ͻͷǤʹȀȋͳͲʹǤʹȌǡ
ʹͲͷǤͷȀ ȋͶͲǤͳȌǡ ͳͲͳǤͻȀ ȋʹ͹ǤʹȌ  ͸Ͳ͵ǤͶȀ ȋͺͻǤͳȌǡ Ǥ  





preeclampsia. Non-response analysis showed that those women without follow-up 
           	ǡ
	ǡ  Ǧ͸ 	 ȋSupplemental Table S2.2.1). Supplemental Table S2.2.2 
shows the correlation between all fatty acid concentrations.
Table 2.2.1.  Maternal characteristics (n=6,823)1
Maternal characteristics Value




ǡȋȌǡȋͻͷΨȌ 20.5 (16.5, 24.9)
ǡǤȋΨȌ
 695 (11.1)






  Nulliparous 3790 (56.1)
  Multiparous 2968 (43.9)
Total calorie intake, kcal, mean (SD) 2043 (568)
	ǡǤȋΨȌ
 3654 (71.6)
  No 1450 (28.4)
ǡǤȋΨȌ
 1125 (18.7)
  No 4889 (81.3)
Saturated fatty acids (SFAs)
Total SFAs 695.2 (102.2)
Myristic acid (C14:0) 10.5 (3.6)
ȋͳ͸ǣͲȌ 493.9 (76.6)
Stearic acid (C18:0) 185.0 (27.8)














Maternal fatty acids and blood pressure development during pregnancy
Figure 2.2.1 (A and B)  shows the systolic and diastolic blood pressure development 
		Ǥ
ϐ
total SFA (P value<0.05). 
The steepest increase in systolic blood pressure was also observed for women in 
	ȋP value<0.05). Diastolic blood pressure showed a mid-
  	ǡ 
	ȋP value<0.05). As compared to 
	ǡ	
a higher systolic blood pressure throughout pregnancy. No differences in diastolic 
	Ǥ
Table 1 Maternal characteristics (n=6,823)1 (continued)
Maternal characteristics Value
ԃǦȋͳͺǣ͵͸Ȍ 1.5 (0.68)
Arachidonic acid (C20:4n6) 156.5 (32.6)












Second trimester placental resistance indices
ǡȋȌ 1.2 (0.19)
ǡȋȌ 0.54 (0.09)







1   ȋ Ȍ   ȋͻͷΨ Ȍ    ȋ ȌǤ  





Figure 2.2.2 (A and B)  shows the systolic and diastolic blood pressure develop-

















 Table 2.2.2 shows the associations of different fatty acid concentrations with 
blood pressure in each trimester of pregnancy from regular linear regression 
Ǥ	
ϐȋP values<0.05). Among the 





lower second and third trimester systolic and diastolic blood pressure (all P val-
δͲǤͲͷȌǤǦ͸	ǡ-
ϐǡ
whereas higher concentrations of AA were associated with a higher second and third 











associations were observed in other trimesters.
Table 2.2.2. Associations of maternal fatty acid concentrations with blood pressure development during 
pregnancy1
Maternal fatty acids in SD
Differences in blood pressure (mmHg) in each trimester 
ȋͻͷΨϐȌ	

















































































































































































































1   ϐ ȋͻͷΨϐ Ȍ  ϐ     
Ǥ
ǡǡǡǡǡǡǡ
use, alcohol consumption, and total calorie intake during pregnancy.
ʹǤʹ

Maternal fatty acid concentrations and placental vascular function
Table 2.2.3  shows that higher total SFA concentrations were not associated with 
Ǥ	
concentrations were only associated with lower second and third trimester umbilical 
ȋǣǦͲǤͲͷȋͻͷΨǣǦͲǤͲͻǡǦͲǤͲʹȌǦͲǤͲͷȋͻͷΨǣ
ǦͲǤͲͻǡ ǦͲǤͲʹȌ  	ȌǤ  
	ǡ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
         
indices (all P values<0.05). No consistent associations were observed among n-3 
	  Ǥ Ǧ͸
	
   ȋǣ ͲǤͲ͸ ȋͻͷΨǣ ͲǤͲʹǡ ͲǤͳͲȌ  ͲǤͲͷ ȋͻͷΨǣ
ͲǤͲͳǡͲǤͲͻȌǦ͸	Ȍǡ-
     Ǧ͸ 	   
 Ǥ   Ǧ͸ȀǦ͵ 	      
ȋǣǦͲǤͲͶȋͻͷΨ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Maternal fatty acid concentrations and the risk of gestational hypertensive 
disorders
Table 2.2.4  shows that higher total SFA concentrations were associated with the 
risk of gestational hypertensive disorders, gestation hypertension and preeclampsia 
ȋͳǤʹ͵ȋͻͷΨǣͳǤͲͻǡͳǤ͵͹ȌǡͳǤͳͻȋͻͷΨǣͳǤͲͶǡͳǤ͵͹ȌͳǤʹ͹ȋͻͷΨǣͳǤͲͺǡͳǤͷͳȌ
per SD increase in total SFAs). Among the individual SFA concentrations, only stearic 
acid tended to be associated with the risk of gestational hypertensive disorders. No 
ϐ 	ǡǦ͵	Ǧ͸	 
risk of gestational hypertensive disorders were present.
Table 2.2.3.  Associations of maternal fatty acid concentrations with placental vascular function1
Maternal fatty acids in SD ȋͻͷΨϐȌ
acid concentrations











Saturated fatty acids (SFAs)
Total SFAs -0.03 (-0.06, 0.01) -0.02 (-0.05, 0.01) -0.01 (-0.04, 0.03) -0.02 (-0.05, 0.01) 0.01 (-0.02, 0.05)
Myristic acid (C14:0) -0.04 (-0.07, -0.01)* -0.02 (-0.06, 0.01) -0.02 (-0.05, 0.01) -0.02 (-0.06, 0.01) -0.02 (-0.06, 0.01)
ȋͳ͸ǣͲȌ -0.03 (-0.06, -0.01)* -0.04 (-0.07, -0.002) -0.03 (-0.06, -0.001) -0.01 (-0.04, 0.03) -0.01 (-0.03, 0.03)
Stearic acid (C18:0) 0.03 (0.01, 0.06)* 0.02 (-0.01, 0.06) 0.03 (0, 0.05) 0.01 (-0.03, 0.04) 0.02 (-0.01, 0.05)
Monounsaturated fatty acids (MUFAs)
	 -0.05 (-0.09, -0.02)** -0.01 (-0.04, 0.02) -0.05 (-0.09, -0.02)** -0.01 (-0.04, 0.02) 0.01 (-0.03, 0.04)
ȋͳ͸ǣͳ͹Ȍ -0.04 (-0.07, -0.01)* -0.03 (-0.06, -0.01)** -0.03 (-0.06, 0.01) -0.01 (-0.04, 0.01) -0.01 (-0.04, 0.03)
ȋͳͺǣͳͻȌ -0.004 (-0.03, 0.03) -0.05 (-0.09, -0.02)** -0.02 (-0.05, 0.01) -0.06 (-0.09, -0.02)** 0.01 (-0.03, 0.04)
n-3 Polyunsaturated fatty acids (PUFAs)
Ǧ͵	 0.03 (0.01, 0.06)* -0.01 (-0.05, 0.02) -0.02 (-0.05, 0.01) -0.01 (-0.05, 0.02) -0.02 (-0.06, 0.01)
ȽǦȋͳͺǣ͵͵Ȍ 0.01 (-0.02, 0.04) -0.02 (-0.05, 0.01) -0.01 (-0.04, 0.02) -0.02 (-0.05, 0.02) -0.01 (-0.04, 0.03)
ȋʹͲǣͷ͵Ȍ 0.02 (-0.01, 0.05) -0.01 (-0.04, 0.02) -0.04 (-0.07, -0.01)* 0.003 (-0.03, 0.04) -0.04 (-0.07, -0.01)*
ȋʹʹǣ͸͵Ȍ 0.03 (0.01, 0.06)* -0.005 (-0.04, 0.03) -0.01 (-0.04, 0.02) -0.003 (-0.04, 0.03) -0.01 (-0.05, 0.02)
n-6 Polyunsaturated fatty acids (PUFAs)
Ǧ͸	 -0.01 (-0.04, 0.02) 0.06 (0.02, 0.10)** 0.03 (-0.001, 0.06) 0.05 (0.01, 0.09)* 0.01 (-0.03, 0.04)
ȋͳͺǣʹ͸Ȍ -0.01 (-0.04, 0.02) 0.04 (0, 0.07) 0.01 (-0.02, 0.04) 0.01 (-0.02, 0.05) -0.01 (-0.04, 0.03)
ԃǦȋͳͺǣ͵͸Ȍ -0.01 (-0.04, 0.02) 0 (-0.03, 0.03) -0.01 (-0.04, 0.02) -0.002 (-0.03, 0.03) -0.01 (-0.04, 0.02)
Arachidonic acid (C20:4n6) 0.03 (0, 0.06) 0.04 (0.01, 0.07) 0.03 (0.01, 0.06)* 0.06 (0.03, 0.09)** 0.03 (-0.01, 0.06)








In this population based prospective cohort study, we observed that higher maternal 
	ǡ	ǡϐ-
ter onwards and an increased risk of gestational hypertensive disorders. In contrast, 
 Ǧ͵	Ǧ͸	ǡ 
ǡ 
pregnancy, but not with second and third trimester placental vascular resistance 
indices or the risk of gestational hypertensive disorders. 
Methodological considerations 
This study was embedded in a population-based prospective cohort among 6,823 sub-
ǤǡǦ
ϐǡ
Table 2.2.4.  Associations of maternal fatty acid concentrations with the risk of gestational hypertensive 
disorders1





Saturated fatty acids (SFAs)
Total SFAs 1.23 (1.09, 1.37)* 1.19 (1.04, 1.37)* 1.27 (1.08, 1.51)*
Myristic acid (C14:0) 1.01 (0.90, 1.13) 1.06 (0.92, 1.22) 0.92 (0.77, 1.10)
ȋͳ͸ǣͲȌ 1.10 (0.99, 1.23) 1.05 (0.92, 1.21) 1.17 (0.99, 1.39)
Stearic acid (C18:0) 1.11 (1.00, 1.24) 1.14 (0.99, 1.30) 1.08 (0.92, 1.28)
Monounsaturated fatty acids (MUFAs)
	 0.98 (0.86, 1.10) 0.92 (0.79, 1.07) 1.05 (0.87, 1.27)
ȋͳ͸ǣͳ͹Ȍ 1.09 (0.98, 1.21) 1.08 (0.94, 1.23) 1.09 (0.93, 1.29)
ȋͳͺǣͳͻȌ 0.97 (0.86, 1.10) 0.91 (0.78, 1.06) 1.07 (0.89, 1.28)
n-3 Polyunsaturated fatty acids (PUFAs)
Ǧ͵	 0.91 (0.81, 1.02) 0.93 (0.80, 1.08) 0.88 (0.72, 1.06)
ȽǦȋͳͺǣ͵͵Ȍ 0.93 (0.83, 1.04) 0.89 (0.76, 1.03) 0.99 (0.83, 1.19)
ȋʹͲǣͷ͵Ȍ 0.95 (0.84, 1.07) 1.01 (0.88, 1.16) 0.81 (0.64, 1.02)
ȋʹʹǣ͸͵Ȍ 0.92 (0.82, 1.03) 0.92 (0.79, 1.07) 0.91 (0.76, 1.09)
n-6 Polyunsaturated fatty acids (PUFAs)
Ǧ͸	 0.97 (0.86, 1.10) 1.01 (0.86, 1.19) 0.93 (0.76, 1.13)
ȋͳͺǣʹ͸Ȍ 0.98 (0.87, 1.10) 0.99 (0.85, 1.14) 0.99 (0.83, 1.18)
ԃǦȋͳͺǣ͵͸Ȍ 1.00 (0.90, 1.11) 1.03 (0.90, 1.17) 0.97 (0.82, 1.15)
Arachidonic acid (C20:4n6) 0.99 (0.89, 1.11) 1.02 (0.89, 1.17) 0.94 (0.79, 1.11)









hemodynamic adaptations and gestational hypertensive disorders. The response 
      
   ͸ͳΨǤ
non-response would lead to biased effect estimates if the associations were different 
between those included and not included in the analyses, but this seems unlikely. 
	ǡ         ϐ Ǥ
ǡϐ̱ʹͷΨ
the participating women. It seems unlikely that late enrolled has biased our results. 
ǡ
and preeclampsia, which might indicate a selection towards a healthy, low-risk 
Ǥ 
number of fatty acid concentrations in plasma samples only once during pregnancy. 
	    ϐ        -
ʹǤ33 In 
addition, fatty acid patterns in plasma phospholipids show a relatively high degree of 




large number of potential confounding factors was available in this study, because of 
the observational design, residual confounding due to other socio-demographic and 
lifestyle-related determinants cannot be ruled out.
ϐ
    ϐ      
mortality in adult populations.1-3
   ǡ    ϐǡ  
affect gestational hemodynamic adaptations and predispose to an increased risk of 
gestational hypertensive disorders.23,24,36 
       ϐ   
blood pressure in non-pregnant adult populations.37 A study among 162 healthy sub-
	ǡ
	Ǧ͵	Ǥ38 
Recent meta-analyses including 7 randomized control trials among adults have 
ǡǡǦ͵	ǡ
diastolic blood pressure in all studies combined.39 During pregnancy, few studies as-
ϐǤ




sociated with systolic blood pressure measured in all trimesters during pregnancy.40 




was marginally positively associated with systolic blood pressure, whereas linoleic 
ǡǦ͸	ǡǦ͸	ϐ
pressure. Two small randomized controlled trials from Denmark did not show an 
  	Ǧ ǡ   Ǧ͵ 	  
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ǡ
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         
Ǥ	ϐ-
genesis and placental vascular function.9,44 Thus far, animal studies have shown that 
a high intake of SFAs before and during pregnancy may induce placental vascular 
ǡǡǤ45,46 It has 
Ǧ͵	-
ϐǤ47 A study among 77 
Icelandic healthy pregnant women showed an inverse association between maternal 
Ǧ͵	ϐǤ48 A con-
trol clinical trial in a group of 145 patients suggested that maternal supplementation 
	ǡǡǡ
placentation.49ǡ
placental vascular function, assessed by Doppler ultrasound of umbilical and uterine 
ϐǡǤ-
sistent associations of total and individual fatty acids on placental vascular function. 
	ǡ	ǡ 
  ǡ Ǧ͵Ǧ͸	






a relatively healthy study population. Further studies are needed to replicate our 
ϐǤ
    ϐ ϐ  
gestational hypertensive disorders.14,15,50  Ǧ   
    	     Ǧ͵ 	 
positively associated with the risk of preeclampsia.14,25,51 A study among 1,718 
ǡǡǦ͵	ǡ




acids were associated with an increased risk of gestational hypertensive disorders. 
The difference with other observational studies might be due to the small number 
of gestational hypertensive disorder cases in our study population and differences 
   Ǥǡ  ϐ   ϐ-
ings from a large multicenter trial among 27,000 women, which failed to show any 
protective effect of marine fatty acids on the risk for preeclampsia.53 
The mechanism by which fatty acids may affect hemodynamic adaptations dur-
ing pregnancy remains controversial. SFAs might contribute to increases in blood 
ǡ
then result in the reduction of elasticity.38ǡǦ͵ϐ
 Ǧ͸	 ǡ
by affecting arterial vasodilation, electrolyte balance, and renal release of renin or 
pressor hormones.38,54 The fatty acids are the precursors of the eicosanoids with 
 ǯǤ  ǡ     -
  ǡ





throughout pregnancy. Different fatty acids were not consistently associated with 
 Ǥ	-
ated with an increased risk of gestational hypertensive disorders. Further studies are 
ʹǤʹ

needed to provide more insight into the role that maternal fatty acid concentrations 
play in the etiology and pathophysiology of gestational hypertensive disorders.
References
 ͳǤ  ǡ Ǧ ǡ  ǡ 
 ǡ  ǡ 	 ǡ  ǡ    










 ͷǤ  	ǡ 
 ǡ  ǡ ǡ ǡ  ǡ 

































 ͳ͸Ǥ ǡǡǡ ǡ
Ǥ	Ǧ 















ǡ    Ǥ  



















 ʹͷǤ  ǡ  ǡ 
ǡǡ   Ǥ  Ǧ͵ 










 ʹͺǤ     Ǥ 	      Ǥ  Ǥ
ʹͲͲͶǢʹͺǣ͸͹ǦͺͲǤ
 ʹͻǤ  ǡ  ǡ ǡ  ǡ    Ǥ 	 -





 ͵ͳǤ ǡ ǡ  ǡ    Ǥ  ϐ 







































Group GS. Relations of plasma polyunsaturated Fatty acids with blood pressures during the 26th 




a high monounsaturated fatty acid diet on blood pressure and glucose metabolism in women with 
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No participation in 
follow-up P-value
Age, mean (SD), years 29.7 (5.2) 30.8 (5.3) 0.04
ǡȋȌǡȋȌ 167.3 (7.4) 167.8 (7.3) 0.50




20.7 (16.5, 24.9) 20.5 (17.1, 23.5) 0.22
ǡǤȋΨȌ
 695 (11.1) 18 (18.8) <0.01
  Secondary 2906 (46.3) 48 (50.0)
 2672 (23.5) 30 (31.3)
ǡǤȋΨȌ
 3254 (50.0) 51 (51.0)
0.58Ȃ 3255 (50.0) 49 (49.0)
ǡǤȋΨȌ
  Nulliparous 3791 (56.1) 53 (53.0) 0.47
  Multiparous 2968 (43.9) 47 (47.0)
Total calorie intake, kcal, mean (SD) 2043 (568) 1913 (516) 0.03
	ǡǤȋΨȌ
 3654 (71.6) 51 (67.1) 0.58
  No 1451 (28.4) 25 (32.9)
ǡǤȋΨȌ
 1125 (18.7) 20 (20.8) 0.75
  No 4889 (81.3) 76 (79.2)
Saturated fatty acids (SFAs)
Total SFAs 695.2 (102.2) 717.9 (115.7) 0.04
Myristic acid (C14:0) 10.5 (3.6) 10.4 (3.8) 0.54
ȋͳ͸ǣͲȌ 493.9 (76.6) 510.7 (84.3) 0.04
Stearic acid (C18:0) 185.0 (27.8) 191.3 (31.8) 0.03
Monounsaturated fatty acids (MUFAs)
	 205.5 (40.1) 208.6 (45.1) 0.51
ȋͳ͸ǣͳ͹Ȍ 12.0 (5.6) 12.9 (5.7) 0.13
ȋͳͺǣͳͻȌ 165.7 (32.9) 167.5 (36.1) 0.66
n-3 Polyunsaturated fatty acids (PUFAs)
Ǧ͵	 103.4 (27.3) 103.9 (29.4) 0.95
ȽǦȋͳͺǣ͵͵Ȍ 5.0 (1.9) 4.8 (1.7) 0.24
ȋʹͲǣͷ͵Ȍ 8..4 (5.3) 8.5 (5.7) 0.87
ȋʹʹǣ͸͵Ȍ 76.5 (20.3) 77.1 (21.8) 0.84
n-6 Polyunsaturated fatty acids (PUFAs)
Ǧ͸	 603.4 (89.1) 619.4 (96.1) 0.09
ȋͳͺǣʹ͸Ȍ 361.5 (62.9) 362.0 (61.6) 0.99
ԃǦȋͳͺǣ͵͸Ȍ 1.5 (0.7) 1.5 (0.7) 0.86
Arachidonic acid (C20:4n6) 156.5 (32.6) 165.9 (42.4) <0.01
n-6/n-3 PUFAs ratio 6.2 (1.7) 6.3 (1.7) 0.38
1ȋȌǡȋͻͷΨȌȋΨȌǤǯǦ
















































































































































































































































































































































































































































































































































































































































































































































































































    Ǥ       
with repeatedly measured systolic and diastolic blood pressure were analyzed using unbalanced repeated 
measurement regression models. These models take the correlation between repeated measurements 
     ǡ     Ǥ  
ǡ  ϐ ȋͳȌǤ	 ǡ  
ͶȋͳǢʹǢ͵ǢͶȌ
gestational age. These models can be written as:
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fatty acids and subcutaneous 
fat mass in infancy 
Aleksandra Jelena Vidakovic, Susana Santos, Michelle A. 
Williams, Liesbeth Duijts, Albert Hofman, Hans Demmelmair, 
Berthold Koletzko, Vincent W.V. Jaddoe, Romy Gaillard




Objective: The associations of maternal plasma n-3 and n-6 polyunsaturated fatty 
 ȋ	Ȍ        
Ǥ
Methods: In a population-based prospective cohort study among 904 mothers and 
 ǡ   Ǧ͵  Ǧ͸ 	  
ǦǤǡǡǦǦ-
taneous fat ratio were calculated at 1.5, 6 and 24 months.
Results: Ǧ͵	
ǤǦ͵	ǡ-
ϐ  ǡ  ǡ   ǡ
were associated with higher central-to-total subcutaneous fat ratio at 1.5 months, 
Ǧ͵	Ǧ
to-total subcutaneous fat ratio at 6 months (all P values< 0.05). These associations 
ʹͶǤǦ͸	-
   ǤǦ͸ȀǦ͵
lower central-to-total subcutaneous fat ratio at 1.5 months only (P value<0.05).
Conclusions: Ǧ͵	






ϐǤ1,2 Several in vitro and animal studies 




 ͳǡʹͷͲ Ǧ       Ǧ͵ 	
concentrations during pregnancy tended to be associated with lower total subcuta-
neous fat mass in children aged 3 years.6 In the same study, higher maternal plasma 
Ǧ͸ȀǦ͵	
childhood.6 A Dutch study among 234 mothers and their children showed that higher 
maternal plasma concentrations ǦɀǦȋ
ȌǡǦ͸	ǡ-
ing pregnancy were associated with higher total subcutaneous fat mass measured in 
children aged 7 years.7 In line with these studies, we have previously reported that 
Ǧ͵	 Ǧ͸	 during 
pregnancy were associated with higher total body fat and abdominal fat levels at 6 
Ǥǡϐ	-
centrations during pregnancy on subcutaneous fat mass development throughout 
infancy. Infancy is a period characterized by rapid growth and subcutaneous fat mass 
development and is a well-known critical period for obesity and cardio-metabolic 
diseases later in life.8,9 By assessing these associations in infancy further insight into 
	-
posity in the offspring can be obtained.
ǡ  ǡ   Ǧ    
early pregnancy onwards among 904 mothers and their infants, the associations of 
Ǧ͵Ǧ͸	 during pregnancy with infant subcutane-
ous fat mass measures. 
Methods
Study design
This study was embedded in the Generation R Study, a population-based prospective 
cohort study from early pregnancy onwards among 9,778 mothers and their children 




Additional detailed assessments of fetal and infant growth and development were 
conducted in a subgroup of Dutch mothers and their children from late pregnancy 
Ǥǡͺ ͲΨǤͳǡʹͲͷ-
ers and their singleton children participated in the subgroup study, of whom 1,083 
	ǤͳǡͲͺ͵
ǡͻͲͶ-
sured at the age of 1.5, 6 or 24 months (Flow chart is given in Supplementary Figure 
S3.1.1). 
Maternal fatty acid status 
Maternal non-fasting venous samples were drawn at a median gestational age of 
ʹͲǤͷȋͻͷΨǣͳͺǤ͸ǦʹʹǤ͹ȌǤǡ
were selected and transported to the Division of Metabolic Diseases and Nutritional 
ǡǤǯǡ
	Ǥ12 After being thawed, the analysis of plasma glycero-
phospholipid fatty acids was performed by a sensitive and precise high-throughput 
method, suitable in large epidemiological studies, as previously described.13 Based on 
ϐǡ	ǡ
have been associated with the risk of obesity in children and adults.6,14 Selected ma-
	Ǧ͵	ǡȽǦȋǡͳͺǣ͵Ǧ͵Ȍǡ
ȋǡʹͲǣͷǦ͵ȌǡȋǡʹʹǣͷǦ͵Ȍǡ
  ȋǡʹʹǣ͸Ǧ͵ȌǤ Ǧ͸	    ȋǡ
ͳͺǣʹǦ͸Ȍǡ ɀǦ  ȋ
ǡ ͳͺǣ͵Ǧ͸Ȍǡ   ȋǡ ʹͲǣʹǦ͸Ȍǡ
ǦɀǦ  ȋ





Body fat measurements during infancy
            ͳǤͷ  ͸
months by using an electronic infant scale and at 24 months by using a mechanical 
ȋǡǡȌǤͳǤͷ͸
months was measured in supine position to the nearest millimeter by using a neona-
tometer and body height at 24 months was measured in standing position by using a 
ȋǡǡȌǤȋȀ2) was 





Growth Standards (results not shown). 
of 1.5, 6 and 24 months on the left side of the body at the biceps, triceps, suprailiacal 
ȋ
ǡ-
ucts) according to standard procedures described in detail previously. Two measure-
ments were performed at each site and the mean was used in the analyses. Intraclass 
ϐͲǤͺͺͲǤ͹͸Ǥ16 
As previously described, we calculated total subcutaneous fat mass from the sum of 
all four skinfold thicknesses, central subcutaneous fat mass from the sum of supraili-
acal and subscapular skinfold thicknesses and peripheral subcutaneous fat mass 
from the sum of biceps and triceps skinfold thicknesses.17 Measurements of body fat 

mass, respectively, in order to undertake informative comparisons between children 
and within children over time. To create total subcutaneous fat mass independent of 
length or height and central subcutaneous fat mass independent of total subcutane-
ǡǦǤ18 
Based on these analyses, total subcutaneous fat mass was only weakly correlated 
 ͳǤͷ͸ʹͶ 
it, whereas a central-to-total subcutaneous fat mass ratio was calculated as central 
divided by total subcutaneous fat mass. The central-to-peripheral subcutaneous fat 
mass ratio was calculated as central divided by peripheral subcutaneous fat mass.
Covariates
   ǡ   ȋǡǡ Ȍǡ
parity (nulliparous, multiparous), prepregnancy weight, smoking habits during 
pregnancy (no, yes) and folic acid supplement use (no, yes) using self-reported 
Ǥǡ
 ȋȀ2). First trimester maternal nutri-
       Ǥ19 Information 
ǡǯǡ
obtained from medical records. Gestational weight gain was calculated as the differ-
͵ͲȋͻͷΨǣʹͺǤͷǡ
32.5) and prepregnancy weight. Information about breastfeeding duration and tim-






adiposity measures at 1.5, 6 and 24 months and the change between these time points 
  Ǥ   -
tional age at blood sampling, maternal age, educational level, parity, prepregnancy 
ǡǡǡ
pregnancy, folic acid supplement use, gestational diabetes, gestational hypertensive 
ǡǯǡǦǡ





central-to-peripheral subcutaneous fat mass ratio using linear regression models. In 
ǡǦ͵Ǧ͸	-
centrations during pregnancy with infant overweight and obesity at 24 months (body 
ͺͷthȌǤ
	ǯ




roni correction, we would consider a PͲǤͲͳ͸ϐȋͲǤͲͷȀ
of outcomes). In order to reduce potential bias associated with missing data and to 
maintain statistical power, we performed multiple imputations of missing covariates 
by generating 5 independent datasets using the Markov Chain Monte Carlo method 





Table 3.1.1 shows the maternal and infant characteristics. Mean (SD) second tri-
mester maternal concentrations of total glycerophospholipid bound n-3 and n-6 
	ͳͳͳǤͶ ȋʹͷǤͺȌȀ ͷͻʹǤ͸ ȋͺ͸ǤͲȌȀǡ  (Table 3.1.2). 
Non-response analyses showed that as compared to mothers and infants with follow-
 
			
up measurements, mothers without follow-up measurements were slightly younger 
and their infant were breastfed for a shorter period (P<0.05) (Supplementary 
Table S3.1.1). ǡ    Ǧ͵	
concentrations compared to those not included (Supplementary Table S3.1.2). 
 ϐ    	    
Supplementary Table S3.1.3.
Table 3.1.1.  Characteristics of mothers and their infant (N = 904)1
Maternal characteristics Value
Age (years), mean (SD) 31.9 (4.0)

	ȋȌǡȋͻͷΨȌ 20.5 (18.6, 22.7)
ǦȋȀ2), mean (SD) 23.4 (4.1)
Gestational weight gain (kg), mean (SD) 10.0 (4.5)
ǡǤȋΨȌ 574 (64.0)
ǡǤȋΨȌ 555 (61.4)










ȋȌǡȋͻͷΨȌ 40.3 (35.8, 42.4)
Birth weight (g), mean (SD) 3509 (544)




ȋȀ2), mean (SD) 15.1 (1.4)
Total subcutaneous fat mass (mm), mean (SD) 24.0 (7.3)
Central-to-total subcutaneous fat mass ratio, mean (SD) 0.5 (0.1)
Central-to-peripheral subcutaneous fat mass ratio, mean (SD) 1.0 (0.2)
6 months
ȋȀ2), mean (SD) 16.8 (1.3)
Total subcutaneous fat mass (mm), mean (SD) 27.0 (6.4)
Central-to-total subcutaneous fat mass ratio, mean (SD) 0.5 (0.1)
Central-to-peripheral subcutaneous fat mass ratio, mean (SD) 0.9 (0.2)
24 months
ȋȀ2), mean (SD) 15.9 (1.3)
Total subcutaneous fat mass,  mean (SD), mm 27.3 (7.2)
Central-to-total subcutaneous fat mass ratio, mean (SD) 0.4 (0.1)
Central-to-peripheral subcutaneous fat mass ratio, mean (SD) 0.8 (0.2)






Maternal PUFA levels and infant fat mass




total subcutaneous fat mass ratio at 1.5 months (all PδͲǤͲͷȌǤǡ
Ǧ͵	ǦǦ
total subcutaneous fat mass ratio at the age of 6 months (P value< 0.05). Maternal 
Ǧ͵ 	     ǦǦ  
ʹͶǤ
are given in Supplementary Table S3.1.4. Supplemental Table S3.1.5  shows that 
Ǧ͵	ǡϐǡ-
sociated with a decrease in central-to-total subcutaneous fat mass ratio from 1.5 to 
24 months, but no associations were found for total subcutaneous fat mass.
Table 3.1.4  ǡ ǡǦ͸	
levels were associated with a lower infant total subcutaneous fat mass at 1.5 months 
(PδͲǤͲͷȌǡǦǦ
ǤǦ͸	
levels with infant adiposity measures were present at 1.5, 6 or 24 months.  Similar re-
Supplementary Table 
S3.1.6. Supplemental Table S3.1.7      




Total PUFA 704.1 (96.4) 42.5 (1.6)
Total n-3 PUFA 111.4 (25.8) 6.8 (1.4)
 5.4 (1.6) 0.3 (0.1)
 10.1 (5.3) 0.6 (0.3)
 12.9 (3.9) 0.8 (0.2)
 81.4 (19.4) 5.0 (1.1)
Total n-6 PUFA 592.6 (86.0) 36.3 (2.0)
 348.9 (59.6) 21.4 (2.5)

 1.5 (0.7) 0.1 (0.0)
 8.3 (1.7) 0.5 (0.1)

 63.4 (16.3) 3.9 (0.7)
    AA 155.9 (31.7) 9.5 (1.4)
    DTA 6.9 (2.0) 0.4 (0.1)
1Values represent means (SDs).
ǣ ǣ ȽǦ Ǣ ǣ  Ǣ 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































with an increase in total subcutaneous fat mass over infancy, and higher AA levels 
Ǥ
Ǧ͵Ǧ͸	
central-to-peripheral subcutaneous fat mass as compared to the results with central-
to-total subcutaneous fat mass (Supplementary Tables S3.1.8-S3.1.9ȌǤ
maternal AA levels were associated with a lower risk of infant overweight at 24 
ǡǦ͵Ǧ͸	
risk of infant overweight (Supplementary Table S3.1.10).
Maternal n-6/n-3 PUFA ratio and infant fat mass
Figure 3.1.1  shows that higher Ǧ͸ȀǦ͵	



















































































































In this population-based prospective cohort study, we observed that higher maternal 
Ǧ͵	ǦǦ












ments. The non-response could lead to biased effect estimates if the associations of 




concentrations in plasma samples once during pregnancy. No information was avail-
	  Ǥǡ	
 ϐ  ʹ
weeks and seem to be reasonable indicators for the recent intake.20
thickness as a measure of subcutaneous fat mass and therefore could not estimate 
ǡǦǤǡϐ-
ͻͲΨǦ
seems to increase only from the second year of life onwards.21,22
infant fat mass outcomes. Since these outcomes are strongly correlated, we did not 
  Ǥ23ǡ ϐ-
ǤǡǦ͵	
ǦǦ͸ǡǦǦ







might still be an issue.
ϐ
    Ǧ͵ Ǧ͸	    -
mal fetal and infant growth and development.24 Rapid weight gain and increased 
fat mass levels during infancy may be critical for the development of adiposity in 
later life.8,9,25,26ǡ
 	     
throughout infancy. 
      Ǧ͵ 	   Ǧ͸ 	 -
centrations during pregnancy are associated with higher childhood body mass 
Ǥ6,7	Ǥ




ϐǤ28 In this 




limited information about body fat distribution.29 Body fat distribution may be more 
ǦǤ30,31
Ǧ͵	Ǧ͸	-
trations during pregnancy were associated with higher total body fat and abdominal 
 ͸Ǥǡ	
concentrations with offspring fat mass outcomes at younger ages. Skinfold thick-
nesses can be used to estimate total and regional subcutaneous adiposity.32 A study 
ͳǡʹͷͲǦǡ
Ǧ͵	
blood, were associated with lower total subcutaneous fat mass measured at the age 
of 3 years.6 ǡǦ͸	
      Ǧ͸ȀǦ͵ 	   
subcutaneous fat mass at the age of 3 years.6 The INFAT randomized trial showed 
Ǧ͵	ǡǦ͸	ǡ





centrations with infant total subcutaneous fat mass from 1.5 months to 24 months 
ǤǦ͵	ǡ
associated with higher central-to-total subcutaneous fat mass ratio at 1.5 months. 
ǡ   Ǧ͵	    
central-to-total subcutaneous fat mass ratio at 6 months. The observed associations 
 Ǥ Ǧ͸	-
trations were associated with lower total subcutaneous fat mass at 1.5 months, 
but not with other infant adiposity measures or at any other time points. Based 
 ϐǡ   Ǧ͵	




   Ȃ
ȋǦɀȌǡ
of subcutaneous fat mass, but not visceral fat mass, in adults.34,35ǡ
Ǧ͵	




and their potential critical periods. 
Conclusion
 Ǧ͵ 	         
ǤǦ͸	-
sistently associated with infant subcutaneous fat mass measures. Further studies are 
	
mass development throughout early infancy. 
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Mothers with singleton live birth 
		++	
Excluded due to missing fatty acids 
measurements in mid-pregnancy  
		;&!	
Mothers with available fatty acids 


















































































Excluded due to no postnatal visit at the ages of 
1.5, 6 and 24 months or missing data on body 
mass index and skinfold thicknesses at the ages 
of 1.5, 6 and 24 months 
!
			
Table S3.1.1.  





No participation in 
follow-up
N = 179 P-value
Maternal characteristics
Age (years), mean (SD) 31.9 (4.0) 30.7 (4.1) <0.01

	ȋȌǡȋͻͷΨȌ 20.5 (18.6, 22.7) 20.5 (18.6, 22.6) 0.56
ǦȋȀ2), mean (SD) 23.4 (4.1) 23.5 (4.3) 0.73
Gestational weight gain (kg), mean (SD) 10.0 (4.5) 10.4 (4.7) 0.54
ǡǤȋΨȌ 574 (64.0) 102 (58.0) 0.13
ǡǤȋΨȌ 555 (61.4) 98 (55.4) 0.07
Total energy intake (kcal), mean (SD) 2126 (486) 2167 (497) 0.41
ǡǤȋΨȌ 198 (24.1) 45 (27.1) 0.22
	ǡǤȋΨȌ 676 (90.7) 139 (90.2) 0.35

ǡǤȋΨȌ 10 (1.1) 1 (0.6) 0.45

ǡǤȋΨȌ 67 (7.6) 7 (4.1) 0.15
Infant characteristics
ǡǤȋΨȌ 464 (51.3) 98 (55.1) 0.34

ȋȌǡȋͻͷΨȌ 40.3 (35.8, 42.4) 40.3 (34.8, 42.2) 0.66
Birth weight (g), mean (SD) 3509 (544) 3513 (591) 0.82
Breastfeeding duration (months), mean (SD) 4.5 (3.8) 3.5 (3.6) 0.01
ȋΨȌε͸ 147 (18.3) 11 (8.9) 0.07
1ȋȌǡȋͻͷΨȌȋΨȌǤǯǦ
ǦǦǡɖ2-test for dichotomous variables.
ǣ	ǣǢǣǤ
 !






No participation in 
follow-up
N = 179 P-value
Total PUFA
ȋȀȌ 704.1 (95.4) 702.3 (90.7) 0.86
ȋΨȌ 42.5 (1.6) 42.3 (1.7) 0.10
Total n-3 PUFA
ȋȀȌ 111.4 (25.8) 107.5 (25.3) 0.07
ȋΨȌ 6.8 (1.4) 6.6 (1.4) 0.01

ȋȀȌ 5.4 (1.6) 5.3 (1.7) 0.49
ȋΨȌ 0.3 (0.1) 0.3 (0.1) 0.25
EPA
ȋȀȌ 10.1 (5.3) 9.8 (5.5) 0.45
ȋΨȌ 0.6 (0.3) 0.6 (0.3) 0.33
DPA
ȋȀȌ 12.9 (3.9) 13.2 (4.3) 0.28
ȋΨȌ 0.8 (0.2) 0.8 (0.2) 0.41
DHA
ȋȀȌ 81.5 (19.2) 77.9 (19.5) 0.02
ȋΨȌ 5.0 (1.1) 4.7 (1.1) <0.01
Total n-6 PUFA
ȋȀȌ 592.6 (86.0) 595.4 (80.8) 0.45
ȋΨȌ 36.3 (2.0) 36.3 (2.0) 0.52

ȋȀȌ 348.9 (59.6) 348.7 (55.2) 0.96
ȋΨȌ 21.4 (2.5) 21.3 (2.5) 0.65


ȋȀȌ 1.5 (0.7) 1.5 (0.7) 0.38
ȋΨȌ 0.1 (0.0) 0.1 (0.0) 0.46
EDA
ȋȀȌ 8.3 (1.7) 8.3 (1.7) 0.85
ȋΨȌ 0.5 (0.1) 0.5 (0.1) 0.44


ȋȀȌ 63.3 (16.3) 64.5 (17.0) 0.22
ȋΨȌ 3.9 (0.7) 3.9 (0.7) 0.26
AA
ȋȀȌ 155.9 (31.7) 157.1 (30.9) 0.37
ȋΨȌ 9.5 (1.4) 9.6 (1.4) 0.53
DTA
ȋȀȌ 6.9 (2.0) 7.2 (2.3) 0.01
ȋΨȌ 0.42 (0.1) 0.4 (0.1) 0.01
1ȋȌǤǯǦǦǦ
 ǡ   ɖ2Ǧ   Ǥ ǣ ǣ ȽǦ Ǣ ǣ 
Ǣ 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Central-to-peripheral subcutaneous fat mass ratio in SDS 
ȋͻͷΨϐȌ
1.5 months 6 months 24 months
Change in fat 
mass measures 
from 1.5 to 6 
months
Change in fat mass 
measures from 1.5 
to 24 months
Change in fat mass 































































fat mass ratio ͳǤͷǡ͸ʹͶǦ͵	ǤǦǦ











Central-to-peripheral subcutaneous fat mass ratio in SDS 
ȋͻͷΨϐȌ
1.5 months 6 months 24 months
Change in fat mass 
measures from 
1.5 to 6
Change in fat mass 
measures from 1.5 
to 24 months
Change in fat mass 
measures from 6 
to 24 months
Total -0.07 (-0.14, 0.01) 0.03 (-0.04, 0.10) -0.01 (-0.09, 0.07) 0.11 (0.01, 0.21)* 0.09 (-0.04, 0.21) -0.03 (-0.15, 0.08)
 -0.03 (-0.10, 0.05) 0.03 (-0.04, 0.10) 0.01 (-0.07, 0.09) 0.06 (-0.05, 0.16) 0.04 (-0.08, 0.16) -0.02 (-0.14, 0.10)

 -0.06 (-0.14, 0.01) 0.02 (-0.05, 0.09) -0.02 (-0.10, 0.06) 0.09 (-0.01, 0.20) 0.07 (-0.05, 0.19) -0.06 (-0.18, 0.06)
 -0.02 (-0.10, 0.05) 0.05 (-0.03, 0.12) -0.05 (-0.12, 0.03) 0.05 (-0.05, 0.16) 0.03 (-0.09, 0.14) -0.12 (-0.23, -0.01)*

 -0.04 (-0.11, 0.04) 0.06 (-0.01, 0.14) -0.06 (-0.14, 0.03) 0.10 (-0.01, 0.20) 0.04 (-0.08, 0.16) -0.13 (-0.25, -0.01)*
AA -0.02 (-0.10, 0.05) -0.04 (-0.11, 0.04) 0.01 (-0.08, 0.08) -0.02 (-0.13, 0.09) 0.02 (-0.10, 0.14) 0.06 (-0.06, 0.18)
DTA -0.04 (-0.12, 0.03) -0.01, -0.08, 0.07) -0.05 (-0.13, 0.03) 0.06 (-0.05, 0.17) 0.04 (-0.08, 0.17) -0.10 (-0.13, 0.11)
1ϐȋͻͷΨϐȌϐǦǦ
fat mass ratio ͳǤͷǡ͸ʹͶǦ͸	ǤǦǦα
ȋԝΪԝȌȀǤ
2ǡǡǡǡǦǡ
maternal total energy intake, smoking habits and weight gain during pregnancy, folic acid supplement use, gestational diabetes, 
  ǡ ǯ ǡ  Ǧ   Ǧ ǡ 
ȋ͸ʹͶȌǤȗǦδͲǤͲͷǤ
ǣ ǣ  Ǣ 
 ǦɀǦ Ǣ ǣ  Ǣ ǣ  ǢǢ 
ǣ
ɀǦǢǣǢ	ǢǤ
Table S3.1.10.  Ǧ͸	ͳǤͷǡ͸ʹͶ
months (N =904)1-2
Maternal PUFAs in SDS Overweight risk at 24 monthsOdds Ratio (95% CI)1
Total n-3 PUFA 1.06 (0.84, 1.33)
 1.12 (0.90, 1.39)
 1.08 (0.86, 1.34)
 0.86 (0.67, 1.09)
 1.07 (0.85, 1.35)
Total n-6 PUFA 1.04 (0.83, 1.30)
 1.20 (0.10, 1.49)

 0.89 (0.71, 1.14)
 1.22 (0.10, 1.49)

 1.18 (0.94, 1.47)
AA 0.74 (0.59, 0.92)*




maternal total energy intake, smoking habits and weight gain during pregnancy, folic acid supplement use, gestational diabetes, 
  ǡ ǯ ǡ  Ǧ   Ǧ ǡ 
ǤȗǦδͲǤͲͷǤ
ǣ ǣ  Ǣ 






fatty acids and childhood 
adiposity outcomes
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Background:     ȋ	Ȍ  
pregnancy may have persistent effects on growth and adiposity in the offspring. A 
suboptimal maternal diet during pregnancy might lead to fetal cardio-metabolic 
Ǥ
Objective: 	
pregnancy with childhood general and abdominal fat-distribution measures.
Design: In a population-based prospective cohort study among 4,830 mothers and 






Results:       Ǧ͵ 	 ǡ 






Ȍ          ǡ
Ȁ  Ǧ  ȋP val-
δͲǤͲͷȌǡ   Ǥ    ϐǡ 
Ǧ͸ȀǦ͵	
and abdominal fat mass levels.
Conclusions: Ǧ͵	Ǧ͸	-
trations during pregnancy are associated with higher total body fat and abdominal fat 
levels in childhood. Further studies are needed to replicate these observations and 





Fetal life and infancy are critical periods for the development of obesity in later 
life.1 Maternal and fetal nutrition might affect fetal and childhood growth and the 
  Ǥ  ȋ	Ȍ
critical nutrients for fetal development.2 Animal studies suggest that supplement-
Ǧ͵	
offspring body weight and less fat accumulation.3 In humans, a study among 293 
ǦǦ͵	Ǧ͸	

with a higher fat mass in children aged 4 to 6 years.4 Furthermore, higher maternal 
  ǦɀǦ  ȋ
Ȍǡ  Ǧ͸ 	ǡ  
ǡ
among 234 children aged 7 years.5     
relationships between early life fatty acid status and childhood obesity have used 
Ǥǡ
mass and provides no insight in body fat distribution.6,7 Studies among adults and 




and fat mass development.4,5,11-13 Thus far, results from observational studies and 
randomized controlled trials are not consistent.14,15
ǡ  ǡ   Ǧ    
early pregnancy onwards among 4,830 mothers and their children, the associations 
  Ǧ͵  Ǧ͸ 	     
    ϐ   ǡ    
ȀǦǦȋȌ
and pre-peritoneal abdominal fat area measured by ultrasound. Additionally, we 

socio-demographic and lifestyle-related characteristics. 
Methods
Study design
This study was embedded in the Generation R Study, a population-based prospec-






January 2006 were enrolled in the study. In total, 8,879 mothers were enrolled dur-
ǡ͹ǡͲ͹ʹ	
and 6,925 gave birth to singleton live born children. Childhood follow up data were 
available in 4,830 of these children (Flow chart is given in Supplemental Figure 
S3.2.1).
Maternal fatty acid status
Maternal venous samples were drawn at a median gestational age of 20.5 weeks 
ȋͻͷΨ ǣ ͳ͸Ǥͷǡ ʹͶǤͻȌǤ   	 ǡ   
were selected and transported to the Division of Metabolic Diseases and Nutritional 
ǡǤǯǡǤ
  ǡ      	 -
tion was performed by a sensitive and precise high-throughput method, suitable in 
large epidemiological studies, as previously described.18	
        ȋ
ǡΨȌǤ19,20ϐǡ
	
and metabolic outcomes in adults and maternal and fetal pregnancy outcomes.4,21-24 
  	 ǣ  Ǧ͵ 	 ǡ  
ȽǦ  ȋǡͳͺǣ͵Ǧ͵Ȍǡ  ȋǡʹͲǣͷǦ͵Ȍǡ-
  ȋǡ ʹʹǣͷǦ͵Ȍǡ   ȋǡ ʹʹǣ͸Ǧ͵ȌǤ  Ǧ͸
	     ȋǡ ͳͺǣʹǦ͸Ȍǡ ɀǦ  ȋ
ǡ
ͳͺǣ͵Ǧ͸Ȍǡ   ȋǡ ʹͲǣʹǦ͸Ȍǡ ǦɀǦ  ȋ
ǡ





Childhood fat distribution outcomes 
At a median age of 6 years, height and weight without shoes and heavy clothing were 





 ȋȌ  ȋǡ ʹͲͲͺǢ 
ǦȌ     

	
ǡ  ͳʹǤ͸ ȋ
ǦȌǤ26 DXA can accurately detect whole body 
fat mass and regional body fat mass and has been validated against CT.26,27 Total fat 
mass (kilograms) was calculated as a percentage of total body weight (kilograms) 
ǤȀǤȀ
   ϐ          
ǡǡȀǤ27
Ǧ
as measure of visceral abdominal fat, as previously described.28ϐǡǦ-




starting from the reference point in direction of the navel. 
Covariates





up to 30 weeks of gestation was calculated as the difference between maternal weight 
͵ͲȋͻͷΨǡʹͺǤͶǦ͵ʹǤͻȌǦ
before pregnancy. As previously described, we used gestational weight gain until 30 




0.87, P< 0.001).     -
tional information during pregnancy. Information about pregnancy complications, 
ǡǤ31,32 In-
formation about breastfeeding, timing of introduction of solid foods and average TV 
Ǥ33 Information about infant 
	ͳ͵ǡʹͳͳǦ




       	  
childhood adiposity outcomes at the age of 6 years using linear regression models. 
Because the abdominal
preperitoneal fat area was not normally distributed, we log transformed this vari-
able for additional analyses. To enable comparison of effect estimates, we constructed 




  ǡ  ǡ ǡ ǡ  
ǡ͵Ͳǡ




    Ǥ 
Ǥ






to reduce potential bias associated with missing data and to maintain statistical 
power, we performed multiple imputations of missing covariates by generating 5 
independent datasets using the Markov Chain Monte Carlo method after which the 





Table 3.2.1  shows the maternal and childhood characteristics. Mean (SD) second 
Ǧ͵Ǧ͸	ͳͲͷǤͲȀȋʹ͹ǤͷȌ
͸ͲͶǤʹȀȋͺͺǤ͸Ȍǡ  (Table 3.2.2) Non-response analyses showed 

	
that as compared to children with follow-up measurements, those without follow-up 
measurements had a lower gestational age at birth and lower birth weight (Supple-
mental Table S3.2.1). ǡǦ͵	
Ǧ͸ȀǦ͵	ȋSupplemental 
Table S3.2.2ȌǤϐ	-
hood body fat outcomes are shown in Supplemental Table 3.2.3. 
 Table 3.2.1.  Characteristics of mothers and their children (N =4,830)1
Value
Maternal characteristics
Age, median (y) 30.9 (19.9, 39.3)

	ȋȌ 20.5 (16.5, 24.9)
ȋȀ2) 23.6 ± 4.2












Birth and infant characteristics
ǡǤȋΨȌ 2413 (50.0)
Gestational age at birth (weeks) 40.1 (35.8, 42.3)






Age at follow up (y) 6.0 (5.6, 7.9)
ȋȀ2) 16.2 ± 1.9
	ȋΨȌ 24.9 ± 5.7
Ȁ 0.3 ± 0.1





Maternal n-3 PUFA concentrations and childhood body fat outcomes
Table 3.2.3     ǡ Ǧ͵	-
centrations and concentrations of each n-3 fatty acid individually were associated 
    ǡ    ǡ Ȁ
gynoid fat mass ratio and abdominal preperitoneal fat mass area (all P values <0.05). 
ǡǦ͵	
Ȁ
fat mass ratio (all PδͲǤͲͷȌǡǦ




factors separately are given in Supplemental Table S3.2.4  and show that pregnancy 
   Ǧ͵	-
Ǥ
ϐǤ
Table 3.2.2.  	ȋαͶǡͺ͵ͲȌ1
ȋȀȌ
Percentage by weight of 
total sum of fatty acids (%)
	 709.3 ± 97.9 43.1 ± 2.0
Total n-3 PUFA 105.0 ± 27.5 6.4 ± 1.5
 5.1 ± 1.9 0.3 ± 0.1
 8.7 ± 5.4 0.5 ± 0.3
 12.1 ± 4.3 0.7 ± 0.2
 77.6 ± 20.4 4.8 ± 1.1
Total n-6 PUFA 604.2 ± 88.6 36.8 ± 2.5
 361.9 ± 63.1 22.3 ± 2.8

 1.5 ± 0.7 0.1 ± 0.0
 8.5 ± 1.9 0.5 ± 0.1

 61.0 ± 16.5 3.7 ± 0.7
    AA 156.4 ± 32.6 9.6 ± 1.6
    DTA 6.9 ± 2.2 0.4 ± 1.1
Ǧ͸ȀǦ͵	 6.1 ± 1.7 -
1Values represent means ± SDs.
ǣ ǣ  Ǣ ǣ ȽǦ Ǣ 
















mass area (all PδͲǤͲͷȌǡǤ-
       Ǧ͸	
concentrations with childhood total body fat mass percentage (difference: 0.08 
ȋͻͷΨǣͲǤͲͷǡͲǤͳͲȌǦ͸	
ȌǤ
in Supplemental Table S3.2.5  and show 
Ǧ͸	Ǥ
Table 3.2.3.  Ǧ͵	ȋαͶǡͺ͵ͲȌ1









fat mass area 
(N=3,912)
Total n-3 PUFAs
Basic model2 -0.09 (-0.12, -0.07)* -0.16 (-0.18, -0.13)* -0.13 (-0.15, -0.10)* -0.09 (-0.12, -0.06)*
Full model3 -0.02 (-0.05, 0.01) -0.07 (-0.10, -0.05)* -0.07 (-0.10, -0.04)* -0.02 (-0.06, 0.01)

Basic model -0.08 (-0.11, -0.05)* -0.10 (-0.12, -0.07)* -0.07 (-0.10, -0.04)* -0.08 (-0.11, -0.06)*
Full model 0.00 (-0.03, 0.03) -0.02 (-0.05, 0.00) -0.02 (-0.05, 0.01) -0.03 (-0.06, -0.00)*
EPA
Basic model -0.08 (-0.10, -0.05)* -0.13 (-0.15, -0.10)* -0.09 (-0.12, -0.07)* -0.07 (-0.10, -0.05)*
Full model -0.02 (-0.04, 0.01) -0.06 (-0.08, -0.03)* -0.04 (-0.07, -0.01)* -0.02 (-0.05, 0.01)
DPA
Basic model -0.05 (-0.08, -0.03)* -0.11 (-0.14, -0.09)* -0.08 (-0.11, -0.06)* -0.04 (-0.07, -0.01)*
Full model -0.00 (-0.03, 0.03) -0.05 (-0.08, -0.03)* -0.05 (-0.08, -0.02)* 0.00 (-0.03, 0.03)
DHA
Basic model -0.08 (-0.11, -0.05)* -0.13 (-0.16, -0.11)* -0.11 (-0.13, -0.08)* -0.07 (-0.10, -0.05)*
Full model -0.02 (-0.04, 0.01) -0.07 (-0.09, -0.04)* -0.06 (-0.09, -0.03)* -0.02 (-0.05, 0.01)
1  ϐ ȋͻͷΨȌ  ϐ    ǡ  
ǡ Ȁ               Ǧ͵ 	
concentrations, respectively. 2        ǡ  ǡ   ȋ
outcomes only). 3	ǡǣǡǡ
ǡǡǦǡ͵Ͳǡǡǡ
folic acid supplement use and total calorie intake during pregnancy and pregnancy complications, gestational age and weight at birth, 
breastfeeding duration, timing of introduction of solid foods and TV watching time, respectively. * P-value<0.05. 




Maternal n-6/n-3 PUFAs ratio and childhood body fat outcomes 
Figure 3.2.1  shows that a higher Ǧ͸ȀǦ͵	
ǡǡȀ







tors are presented in Supplemental Figure S3.2.2.
Table 3.2.4.  Ǧ͸	ȋαͶǡͺ͵ͲȌ1










fat mass area (N=3,912)
Total n-6 PUFA
Basic model2 0.11 (0.08, 0.14)* 0.17 (0.15, 0.20)* 0.12 (0.09, 0.15)* 0.14 (0.11, 0.17)*
Full model3 0.03 (-0.00, 0.06) 0.08 (0.05, 0.10)* 0.06 (0.03, 0.10)* 0.07 (0.04, 0.11)*

Basic model 0.03 (0.00, 0.06)* 0.08 (0.06, 0.11)* 0.07 (0.04, 0.10)* 0.06 (0.03, 0.08)*
Full model 0.01 (-0.02, 0.04) 0.05 (0.03, 0.08)* 0.06 (0.03, 0.09)* 0.03 (-0.00, 0.06)


Basic model 0.03 (-0.00, 0.05) 0.03 (0.01, 0.06)* 0.02 (-0.01, 0.05) 0.06 (0.03, 0.08)*
Full model 0.01 (-0.02, 0.03) 0.01 (-0.01, 0.04) -0.00 (-0.03, 0.03) 0.04 (0.01, 0.07)*
EDA
Basic model -0.00 (-0.03, 0.03) 0.02 (-0.01, 0.05) 0.02 (-0.01, 0.05) 0.01 (-0.02, 0.04)
Full model -0.01 (-0.03, 0.02) 0.00 (-0.02, 0.03) 0.02 (-0.01, 0.05) -0.01 (-0.04, 0.02)


Basic model 0.06 (0.03, 0.09)* 0.06 (0.04, 0.09)* 0.07 (0.04, 0.09)* 0.07 (0.04, 0.10)*
Full model 0.01 (-0.02, 0.03) 0.04 (0.02, 0.07)* 0.05 (0.02, 0.08)* 0.06 (0.03, 0.09)*
AA
Basic model 0.09 (0.06, 0.11)* 0.08 (0.05, 0.10)* 0.03 (-0.00, 0.05) 0.08 (0.05, 0.11)*
Full model 0.01 (-0.02, 0.04) -0.01 (-0.04, 0.02) -0.04 (-0.07, -0.01)* 0.02 (-0.01, 0.05)
DTA
Basic model 0.08 (0.06, 0.11)* 0.08 (0.06, 0.11)* 0.06 (0.03, 0.09)* 0.10 (0.07, 0.12)*
Full model 0.02 (-0.01, 0.05) 0.01 (-0.02, 0.04) 0.01 (-0.02, 0.04) 0.04 (0.01, 0.07)*
1  ϐ ȋͻͷΨȌ  ϐ    ǡ  
ǡ Ȁ               Ǧ͸ 	
concentrations, respectively. 2        ǡ  ǡ   ȋ
outcomes only).3	ǡǣǡǡ
ǡǡǦǡ͵Ͳǡǡǡ
folic acid supplement use and total calorie intake during pregnancy and pregnancy complications, gestational age and weight at birth, 
breastfeeding duration, timing of introduction of solid foods and TV watching time, respectively. * P-value<0.05. 
ǣ ǣ  Ǣ 
 ǦɀǦ Ǣ ǣ  Ǣ 




Additional analysis to take infant PUFA intake into account
ʹǡ͵ͳ͵
     	 Ǥ    
	-
tions (data not shown).
Discussion
In this population based prospective cohort study, we observed that maternal lower 
Ǧ͵	Ǧ͸	
associated with a higher body fat percentage and an adverse general and abdominal 
ǤǦ͵Ǧ͸	-
 
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participated in the follow-up studies at the age of 6 years. The non-response could 
	
with childhood body composition would be different between children included and 
not included in the analyses. Non-response analysis showed that birth weight and 
gestational age at birth were lower among children who were not included in the 
   Ǥǡ Ǧ͸ȀǦ͵	
higher among mothers of children who were not included in the analysis. Selective 
loss to follow up may have led to underestimation of the effect estimates if children 
ϐǦ͸ȀǦ͵
ǦǤ	-
tions in blood samples only once during pregnancy. These concentrations of maternal 
	ϐ	
during the full pregnancy, as this also depends on placental transfer.35ǡ	
 ϐ  ʹ




a regional analysis but cannot differentiate the two abdominal fat compartments.26,27 
          
           
these fat compartments.37 Both DXA and abdominal ultrasound have been validated 
against computed tomography.26,27,37	
concentrations with childhood adiposity outcomes in different regression models 
ȋǢǢ Ǣ Ȍ 
Ǥ

    Ǥ 	  
Ǥ
confounders because of the potential of residual confounding in this observational 
Ǥǡ   
Ǥ-






concentrations and childhood body composition.5 Further studies are needed to 

factors in these observed associations. 
ϐ
  	       Ǥ38 
Ǧ͵	Ǧ͸	








  ͹Ǥ5 In another study among 388 

 Ǧ    Ǧ͸ȀǦ͵ 	      -
 ͳͲ Ǥ41 Another study among 
208 pregnant women in Germany showed that higher concentrations of maternal 
ǡǦ͸	ǡ  ͳ
of age.42 Thus, results from previous observational studies suggest that maternal 
	
and adiposity. Such observational studies may suffer from residual confounding. To 
	
and childhood adiposity outcomes, several randomized trials have been performed. 
A randomized, double-blind clinical trial among 144 pregnant women showed that 
 ʹͲͲǡ Ǧ͵	ǡ-
  ʹͳǡ  
age 6 years.43 A meta-analysis of 6 randomized controlled trials showed no effect 
Ǧ͵	   
preschool children.14 Thus results from these trials do not support the results ob-
  Ǥǡ   ϐ
ǡϐ
to larger population-based samples.
	
more detailed offspring body fat measures. A study among 1,250 mother-child pairs 
ǡǦ͵	ǡ
the maternal diet and in umbilical cord, were associated with lower subcutaneous 
͵Ǥʹ

fat mass measured by the sum of subscapular and triceps skinfold thicknesses at 
the age of 3 years.21ǡǦ͸	




      ͸ Ǥ  Ǧ͵ȀǦ͸
	       Ͷ ǡ  
at 6 years.4 Findings from this latter study suggest that a reduction in maternal n-6 




In the current study, we observed in the basic models that maternal higher n-3 
	    Ǧ͸ 	     
 Ǥǡ   Ǧ
  Ǧ Ǥ ǡ   
         	 
Ǥ
ǡǦ͵	
     ǡ Ȁ  -
tio, a measure of waist-to-hip ratio and abdominal pre-peritoneal fat mass area, a 
  Ǥ Ǧ͵Ǧ	ǡǡǡǡ 







factors on which we had information available. Thus, our results suggest that both 
Ǧ͵	Ǧ͸	-
tions during pregnancy affect childhood total body fat mass and abdominal fat mass 
levels. An adverse body fat distribution seems to be, independently of body mass 
ǡ       ϐǤ10,44,45  
	
Ǥ




cal mechanisms underlying may involve adaptations in fetal fat cell development and 
adipose tissue growth.4,46Ǧ͸	ǡ-




the fetuses reducing both hyperplasia as well as hypertrophy of growing fat depots.48 
       Ǥ   
effect estimates were small and without clinical relevance for individuals, the results 
Ǥǡ
   Ǥ     





maternal and childhood socio-demographic and lifestyle-related characteristics. 
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Body mass index     
Fat mass     	

Android/gynoid fat mass   	

Abdominal pre-peritoneal fat mass  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Table S3.2.1.  





No participation in 
follow-up
N = 2,094 P-value
Maternal Characteristics
Age (y) 30.9 (19.9, 39.3) 28.8 (18.5, 38.7) <0.01

	ȋȌ 20.5 (16.5, 24.9) 20.5 (17.1, 24.9) 0.99
ǦȋȀ2)  23.6 ± 4.2 23.7 ± 4.7 0.48
͵ͲȋȌ 10.4 ± 4.9 10.3 ± 5.4 0.79
ǡǤȋΨȌ 2400 (46.2) 602 (33.0) <0.01
ǡǤȋΨȌ 2917 (61.5) 897 (48.0) <0.01
ǡǤȋΨȌ 2757 (57.5) 1087 (52.7) <0.01
ǡάǡȀ 2048 ± 558 2020 ± 591 0.13
ǤȋΨȌ 738 (17.1) 407 (22.5) <0.01
	ǡǤȋΨȌ 2794 (75.6) 911 (61.4) <0.01
 91 (2.0) 55 (2.9) 0.04
Gestational hypertension 182 (4.0) 58 (3.0) 0.06
Gestational diabetes 44 (0.9) 26 (1.3) 0.17
Childhood characteristics
ǡǤȋΨȌ 2413 (50.0) 1086 (51.9) 0.14

ǡȋͻͷΨȌǡ 40.1 (35.8, 42.3) 40.0 (34.9, 42.4) <0.01
Birth weight, mean ± SD, g 3433 ± 553 3383 ± 579 <0.01
ǡǡǤȋΨȌ 3550 (92.7) 1014 (90.5) 0.02
ǤȋΨȌε͸ 315 (10.4) 78 (10.7) 0.46
Ǧ͵	ȋȀȌ 0.6 (0.4) 0.7 (0.5) <0.01
Ǧ͸	ȋȀȌ 4.7 (2.9) 5.4 (3.9) <0.01
1  ά ǡ ȋͻͷΨ Ȍ     ȋΨȌǤ Ǧ͵ Ǧ͸ 	    















ȋȀȌ 709.3 ± 97.9 702.0 ± 100.7 <0.01
ȋΨȌ 43.1 ± 2.0 43.4 ± 2.1 <0.01
Total n-3 PUFA
ȋȀȌ 105.0 ± 27.5 99.8 ± 26.6 <0.01
ȋΨȌ 6.4 ± 1.5 6.1 ±1.4 <0.01

ȋȀȌ 5.1 ± 1.9 4.8 ± 1.9 <0.01
ȋΨȌ 0.3 ± 0.1 0.3 ± 0.1 <0.01
EPA
ȋȀȌ 8.7 ± 5.4 7.8 ± 5.1 <0.01
ȋΨȌ 0.5 ± 0.3 0.5 ± 0.3 <0.01
DPA
ȋȀȌ 12.1 ± 4.3 11.6 ± 4.4 <0.01
ȋΨȌ 0.7 ± 0.2 0.7 ± 0.2 <0.01
DHA
ȋȀȌ 77.6 ± 20.4 74.1 ± 19.8 <0.01
ȋΨȌ 4.8 ± 1.1 4.6 ± 1.1 <0.01
Total n-6 PUFA
ȋȀȌ 604.2 ± 88.6 602.2 ± 90.8 0.38
ȋΨȌ 36.8 ± 2.5 37.2 ± 2.5 <0.01

ȋȀȌ 361.9 ± 63.1 360.5 ± 62.2 0.41
ȋΨȌ 22.3 ± 2.8 22.6 ± 2.8 <0.01


ȋȀȌ 1.5 ± 0.7 1.5 ± 0.7 0.35
ȋΨȌ 0.1 ± 0.0 0.1 ± 0.0 0.80
EDA
ȋȀȌ 8.5 ± 1.9 8.5 ± 1.9 0.05
ȋΨȌ 0.5 ± 0.1 0.5 ± 0.1 0.41


ȋȀȌ 61.0 ± 16.5 59.2 ± 17.3 <0.01
ȋΨȌ 3.7 ± 0.7 3.7 ± 0.8 <0.01
AA
ȋȀȌ 156.4 ± 32.6 157.3 ± 33.2 0.29
ȋΨȌ 9.6 ± 1.6 9.8 ± 1.6 <0.01
DTA
ȋȀȌ 6.9 ± 2.2 7.1 ± 2.2 <0.01
ȋΨȌ 0.4 ± 1.1 0.4 ± 0.1 <0.01
Total n-6/n-3 PUFAs ratio

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































for pregnancy and childhood factors (N = 4,830)1




Total body fat mass 
percentage (N = 4,706)
Android/gynoid fat 
mass ratio (N = 4,706)
Preperitoneal 
fat mass area (N = 
3,912)
Total n-3 PUFAs
2 -0.01 (-0.04, 0.01) -0.07 (-0.10, -0.05)* -0.07 (-0.10, -0.04)* -0.02 (-0.06, 0.01)
Childhood factors3 -0.08 (-0.11, -0.05)* -0.14 (-0.16, -0.11)* -0.11 (-0.14, -0.08)* -0.07 (-0.10, -0.04)*

 -0.00 (-0.03, 0.02) -0.02 (-0.05, 0.01) -0.02 (-0.05, 0.01) -0.03 (-0.06, 0.00)
Childhood factors -0.07(-0.10, -0.04)* -0.09 (-0.11, -0.06)* -0.06 (-0.09, -0.04)* -0.08 (-0.11, -0.05)*
EPA
 -0.02 (-0.04, 0.01) -0.06 (-0.08, -0.03)* -0.05 (-0.08, -0.02)* -0.02 (-0.05, 0.01)
Childhood factors -0.07 (-0.10, -0.04)* -0.11(-0.14, -0.09)* -0.08 (-0.11, -0.05)* -0.06 (-0.09, -0.03)*
DPA
 0.00 (-0.03, 0.03) -0.05 (-0.07, -0.02)* -0.05 (-0.08, -0.02)* 0.01 (-0.02, 0.04)
Childhood factors -0.05 (-0.08, -0.02)* -0.10 (-0.12, -0.07)* -0.08 (-0.11, -0.05)* -0.03 (-0.06, -0.01)*
DHA
 -0.01 (-0.04, 0.02) -0.06 (-0.09, -0.04)* -0.06 (-0.09, -0.03)* -0.02 (-0.05, 0.01)
Childhood factors -0.07 (-0.10, -0.04)* -0.11 (-0.14, -0.09)* -0.09 (-0.12, -0.07)* -0.06 (-0.09, -0.03)*




total calorie intake during pregnancy and pregnancy complications. 3
birth characteristics, breastfeeding duration, timing of introduction of solid foods and TV watching time, respectively. * P-value<0.05.




Table S3.2.5.  Ǧ͸	
for pregnancy and childhood factors (N = 4,830)1












fat mass area 
(N = 3,912)
Total n-6 PUFA
2 0.02 (-0.01, 0.05) 0.08 (0.05, 0.10)* 0.06 (0.03, 0.10)* 0.07 (0.04, 0.11)*
Childhood factors3 0.10 (0.07, 0.13)* 0.15 (0.12, 0.18)* 0.11 (0.08, 0.14)* 0.13 (0.10, 0.16)*

 0.01 (-0.02, 0.04) 0.05 (0.02, 0.07)* 0.05 (0.02, 0.08)* 0.02 (-0.01, 0.05)
Childhood factors 0.03 (-0.00, 0.05) 0.07 (0.05, 0.10)* 0.06 (0.03, 0.09)* 0.05 (0.02, 0.08)*


 0.00 (-0.03, 0.03) 0.02 (-0.01, 0.04) 0.00 (-0.03, 0.03) 0.04 (0.02, 0.07)*
Childhood factors 0.03 (-0.00, 0.05) 0.03 (0.01, 0.06)* 0.01 (-0.02, 0.04) 0.05 (0.02, 0.08)*
EDA
 -0.01 (-0.03, 0.02) -0.00 (-0.03, 0.02) 0.01 (-0.02, 0.04) -0.01 (-0.04, 0.02)
Childhood factors -0.00 (-0.03, 0.02) 0.02 (-0.01, 0.04) 0.02 (-0.01, 0.05) 0.01 (-0.02, 0.03)


 0.01 (-0.02, 0.04) 0.04 (0.02, 0.07)* 0.05 (0.02, 0.08)* 0.06(0.03, 0.10)*
Childhood factors 0.05 (0.02, 0.08)* 0.06 (0.04, 0.09)* 0.07 (0.04, 0.10)* 0.07 (0.04, 0.10)*
AA
 0.00(-0.03, 0.03) -0.00 (-0.03, 0.03) -0.03 (-0.06, -0.00)* 0.03 (-0.00, 0.06)
Childhood factors 0.08 (0.05, 0.11)* 0.06 (0.03, 0.08)* 0.01 (-0.02, 0.04) 0.07 (0.04, 0.10)*
DTA
 0.02 (-0.01, 0.05) 0.02 (-0.01, 0.05) 0.01 (-0.02, 0.04) 0.05 (0.02, 0.08)*
Childhood factors 0.08 (0.05, 0.10)* 0.06 (0.04, 0.09)* 0.05 (0.02, 0.08)* 0.08 (0.05, 0.11)*




total calorie intake during pregnancy and pregnancy complications. 3
birth characteristics, breastfeeding duration, timing of introduction of solid foods and TV watching time, respectively.* P-value<0.05. 
ǣ ǣ  Ǣ 
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Ŷ  Pregnancy model 
ŸChildhood model  
   ϐ ȋͻͷΨȌ  ϐ       ǡ   
ǡ Ȁ  Ǧ  Ǧ͸ȀǦ͵	
ǡ Ǥ         ǡ  ǡ   ȋ 
ȌǤ	ǡǣǡǡǡ
ǡǦ ǡ ͵Ͳ ǡ ǡ  ǡ 
acid supplement use and total calorie intake during pregnancy and pregnancy complications, gestational age and weight at birth, 
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Background: Suboptimal maternal diet during pregnancy might lead to fetal cardio-
Ǥ
Objectives:    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
ȋ	ȌǤ


















during pregnancy are associated with a lower systolic blood pressure in childhood. 





Suboptimal maternal and fetal nutrition might lead to fetal cardiovascular develop-
       
in later life.1 In humans, support for this hypothesis is largely based on historical 

pregnancy with the development of hypertension in later life.2 Not much is known 
 ϐ     ǡ   
        Ǥ  
been hypothesized that maternal intake of long-chain polyunsaturated fatty acids 
ȋ	Ȍ     Ǥ3,4 During 
	
for maternal tissue and fetal development.5Ǧ͵	
Ǧ͸	   
gestational hypertensive disorders and low birth weight.6-8 A previous study among 
ʹͻ͵Ǧ  Ǧ͸	-
  ǡ   Ǧ͵ 	 ǡ   
higher offspring fat mass.9 In addition, a recent study in rats suggested that moderate 
Ǧ͵	ϐ    
ǡϐ
pressure.6 A study among Dutch children showed that children who received human 
Ǧ͵	ϐ
lower systolic blood pressure at the age of 12 years.10 Thus far, no studies among 
	
with offspring blood pressure.
ǡǦ





This study was embedded in the Generation R Study, a population-based prospec-
tive cohort study from fetal life to adulthood in Rotterdam, the Netherlands.11 The 





were enrolled in the study. In total, 8,879 mothers were enrolled during pregnancy, 
͸ǡͻʹͷ	  
born children. Childhood blood pressure was available in 4,455 of these children 
(Flow chart is given Supplemental Figure S3.3.1). 
Maternal polyunsaturated fatty acid status
Maternal non-fasting venous samples were drawn at a median gestational age of 20.6 
ȋͻͷΨǣͳͺǤͷǦʹ͵ǤʹȌǤ	ǡ
were picked and transported to the Division of Metabolic Diseases and Nutritional 
ǡǤǯǡǤ
ǡ	
was performed by a sensitive and precise high-throughput method, suitable in large 
epidemiological studies, as previously described.12ϐ
ǡ	ǡ
with the risk of cardiovascular disease in adults, and maternal and fetal pregnancy 
outcomes.8,9,13-16   	   Ǧ͵ 	ǡ  
ȽǦȋǡͳͺǣ͵Ǧ͵ȌǡȋǡʹͲǣͷǦ͵Ȍǡ
ȋǡʹʹǣͷǦ͵Ȍǡȋǡʹʹǣ͸Ǧ͵ȌǦ͸	ǡ











four times with one-minute intervals at the right brachial artery with the child in 








Information on maternal age, educational level, ethnicity and maternal folic acid 
supplement use was obtained at enrolment.11  ǡ 
blood pressure at enrolment, and obtained information about maternal prepreg-
   Ǥ   Ǥ  
gain during pregnancy was calculated as the difference between maternal weight at 
third trimester and maternal prepregnancy weight. Information on maternal smok-
         Ǥ
        -
ȋǤǤǡ-
dorp, the Netherlands). 




was obtained from medical records.20,21 Information about breastfeeding and timing 




     	Ψǡ    -
viation difference, with childhood systolic and diastolic blood pressure using linear 




pressure at enrolment, smoking, alcohol consumption, folic acid and homocysteine 
concentrations in plasma, total caloric intake during pregnancy, and pregnancy 











    Ǥ  ϐ  
ǡϐǤ
bias associated with missing data and to maintain statistical power, we performed 
multiple imputations of missing covariates by generating 5 independent datasets 
using the Markov Chain Monte Carlo method after which the pooled effect estimates 
Ǥ





Maternal and childhood characteristics are given in Table 3.3.1.  Second trimester 
 Ǧ͵Ǧ͸	ͳͲͶάʹ͹ǤͷȀͷͻ͹ά
ͺ͹ǤͷȀǡ (Table 3.3.2). Results from the non-response analysis are 
given in Supplemental Table S3.3.1  and showed that mothers who were not in-
cluded in the analyses smoked more often during pregnancy and developed more 
often preeclampsia as compared to those who were included (P values<0.05). Also, 
birth weight, gestational age at birth and breastfeeding duration were lower among 




Table 3.3.1.  Characteristics of mothers and their children (N =4,455)1
Maternal characteristics Value
   Age, (yr) 30.9 (20.0, 39.2)
   Gestational age at enrolment, (wk) 13.8 (9.9-22.6)
ǡȋȀ2) 23.6 ± 4.2
ǡȋȌ 10.4 ± 4.9
ǡȋȌ 116 ± 12.2




ǡȋȀȌ 2051 ± 559
ǡǤȋΨȌ 1037 (26.1)
ǡǤȋΨȌ 2150 (54.7)
ǡȋȀȌ 18.5 ± 9.0







	ǡȋȀȌ 7.9 (0.64, 38.4)
Ǧ͸	ǡȋȀȌ 4.1 (0.03-28.9)
Ǧ͵	ǡȋȀȌ 0.5 (0.00, 3.67)
ǡǤȋΨȌ 2225 (49.9)
   Gestational age at birth, (wk) 40.1 (35.7, 42.4)
   Birth weight, (g) 3436 ± 551
ǡȋΨȌ 3275 (92.8)
ȋΨȌ
       < 3 months
       3-4.9 months




   Age at follow up, (yr) 6.0 (5.7, 7.9)
ǡȋȀ2) 15.8 (13.6, 21.2)
ǡȋȌ 102.6 ± 8.2




Maternal n-3 PUFA wt% and childhood blood pressure
Table 3.3.3  ǡ
ǡǦ͵	Ψϐǡǡ
ΨȋP values 
δͲǤͲͷȌǤ   
ǡǡΨǤ
ǡǦ͵	Ψ
     ȋǣ ǦͲǤʹͺ ȋͻͷΨǣǦ
ͲǤͷͶǡǦͲǤͲ͵ȌǦͲǤʹͻȋͻͷΨǣǦͲǤͷͶǡǦͲǤͲ͵Ȍ
Ǧ͵	Ψǡ ȌǤ    ǡ 
Ǧ͵	ǡΨ
diastolic blood pressure (P values<0.05), but no associations were present in the 
Ǥ




Total PUFAs 700 ± 96.8 -
Total n-3 PUFAs 104 ± 27.5 6.4 ± 1.5
    18:3n-3 5.1 ± 1.9 0.3 ± 0.1
    20:5n-3 8.7 ± 5.4 0.5 ± 0.3
    22:5n-3 12.1 ± 4.3 0.7 ± 0.2
    22:6n-3 77.6 ± 20.5 4.8 ± 1.1
Total n-6 PUFAs 597 ± 87.5 36.8 ± 2.5
    18:2n-6 362 ± 63.5 22.3 ± 2.8
    18:3n-6 1.5 ± 0.7 0.1 ± 0.0
    20:2n-6 8.5 ± 1.9 0.5 ± 0.1
    20:3n-6 61.1 ± 16.5 3.7 ± 0.7
    20:4n-6 157 ± 32.6 9.6 ± 1.6
    22:4n-6 7.0 ± 2.2 0.4 ± 1.1




Maternal n-6 PUFA wt% and childhood blood pressure
Table 3.3.4 ǡǦ͸	ǡΨ
were associated with a higher childhood systolic blood pressure (P values<0.05). 
         
ǤǡǦ͸	Ψ
was associated with a higher childhood systolic blood pressure (difference: 0.36 
 ȋͻͷΨǣ ͲǤͲͻǡ ͲǤ͸ʹȌ      Ǧ͸ 	ΨȌǤ   
   Ǧ͸ 	ǡ   Ψ  
higher childhood diastolic blood pressure (P values<0.05), whereas in the childhood 
Ǧ͸	Ψ-
hood diastolic blood pressure (P values<0.05). No associations were present in the 
Ǥ
Table 3.3.3.  Ǧ͵	Ψ͸ȋαͶǡͶͷͷȌ1
ȋͻͷΨϐȌ











Systolic blood pressure (mmHg)
Basic model2 -0.60 (-0.84, -0.36)* -0.32 (-0.56, -0.08)* -0.30 (-0.54, -0.06)* -0.42 (-0.66, -0.17)* -0.58 (-0.82, -0.34)*
3 -0.33 (-0.59, -0.07)* -0.12 (-0.37, 0.13) -0.07 (-0.32, 0.18) -0.24 (-0.48, 0.01) -0.33 (-0.59, -0.07)*
Childhood model4 -0.35 (-0.58, -0.11)* -0.15 (-0.38, 0.09) -0.08 (-0.31, 0.15) -0.26 (-0.50, -0.03)* -0.37 (-0.59, -0.12)*
Full model5 -0.28 (-0.54, -0.03)* -0.12 (-0.36, 0.12) -0.03 (-0.28, 0.22) -0.22 (-0.46, 0.02) -0.29 (-0.54, -0.03)*
Diastolic blood pressure (mmHg)
Basic model -0.38 (-0.58, -0.17)* -0.19 (-0.40, 0.00) -0.12 (-0.32, 0.08) -0.35 (-0.55, -0.15)* -0.36 (-0.57, -0.16)*
 -0.11 (-0.33, 0.11) -0.04 (-0.25, 0.17) 0.12 (-0.09, 0.34) -0.19 (-0.40, 0.02) -0.13 (-0.35, 0.09)
Childhood model -0.26 (-0.47, -0.06)* -0.13 (-0.33, 0.07) -0.02 (-0.22, 0.18) -0.28 (-0.48, -0.07)* -0.27 (-0.47, -0.06)*











Maternal n-6/n-3 PUFA ratio and childhood blood pressure
Figure 3.3.1 shows that higher Ǧ͸ȀǦ͵	 
a higher childhood systolic and diastolic blood pressure in the basic models (p-
δͲǤͲͷȌǤ        
ǤǡǦ͸ȀǦ͵
	        
ȋǣͲǤʹͶȋͻͷΨǣͲǤͲͻǡͲǤ͵ͻȌǦ͸ȀǦ͵	-
ȌǡǤǯ	
intakes at 13 months did not affect the observed associations (data not shown).
Table 3.3.4.  Ǧ͸	Ψ͸ȋαͶǡͶͷͷȌ1
ȋͻͷΨϐȌ













































































































































In this population based prospective cohort study, we observed that higher maternal 
Ǧ͵	ȋȌǦ͸	-
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  Ǧ͸ȀǦ͵	Ǥ ǡ
   Ǥ       ǡ  ǡ ǡ ǡ
Ǧǡǡǡǡǡ








͸ͶΨ   ǦǤǦ
	
with childhood blood pressure would be different between children included and not 
included in the analyses. Non-response analysis showed various differences between 
Ǥ 
these differences would affect the observed associations materially. Although we 
	ǡ
were measured only once during pregnancy. No information was available about 
	  Ǥ	  -
	Ǥǡ-
	ϐ	
ǡǤ42 Finally, although 
ǡ
residual confounding might still be an issue, as in any observational study. Most im-
portantly, we did not have detailed information about maternal dietary intake during 
	Ǥ
ϐ		ǡ
   Ǥ
	
and observed that the associations were not materially affected. Further studies are 

dietary factors in these observed associations. 
ϐ
Suboptimal nutrition in early life is associated with an increased risk of cardiovas-
cular diseases in later life.22,23 Multiple studies have shown that maternal intake of 
Ǧ	Ǥ4,5 Not much 
	
with offspring cardiovascular and metabolic outcomes in later life. 
ǡ	
concentrations during pregnancy with cardiovascular outcomes in the offspring. A 
ͳǡʹͷͲǦǦ͵	 
was associated with lower adiposity levels in children at age 3 years, whereas a 
Ǧ͸ȀǦ͵	-




associated with an increased risk of obesity and higher fat mass levels in children 
aged 4 and 6 years.9ǡʹͲͺ
ϐϐǦ͸ȀǦ͵	
ratio in the maternal diet on adipose tissue level in infants.24 In our current study, we 
Ǧ͵	Ǧ͸	




 	        
Ǥ  Ǧ͵	ϐ  
leads to a higher blood pressure later in life.25ǡ-
man observational studies and randomized clinical trials has shown that the intake 
Ǧ͵	  
adults and with a reduced risk of coronary heart disease.26 Also, a meta-analysis 
   ϐ   Ǥ27 
 ǡ    Ǧ͵ Ǧ͸	     
    Ǥ     ͳͶ͹   
ǡ  

pressure and diastolic blood pressure at the age of 6 years than those who were 
not supplemented.28 A randomized trial among 83 Danish children at the age of 9 
ϐ
oil supplementation for three months.29 A study among 973 Dutch children showed 

had lower systolic blood pressure at the age of 12 years. This association was not 
ϐǦ͵	ͳʹ
years.10 In line with these studies, our current study suggests that maternal n-3 and 
Ǧ͸ 	   ϐ   
early fetal life onwards. 











ǡ    ʹǡ   -
tion.38Ǧ͵	ϐ
ǦϐǤ39 It has 
ϐǦ͵Ǧ͸	 
optimal cardiovascular development.40,41  ϐ    
Ǧ͸ȀǦ͵	ϐ









pregnancy are associated with a lower systolic blood pressure in childhood. These 
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tation during pregnancy on maternal and neonatal polyunsaturated fatty acid status and pregnancy 
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nutritional fatty acids during pregnancy and lactation on early human adipose tissue development. 
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No participation in 
follow-up
N = 2,470 P value
Maternal Characteristics
   Age, (yr) 30.9 (20.0, 39.2) 29.1 (18.5, 39.1) < 0.01
   Gestational age at intake, (wk) 13.8 (9.9, 22.6) 14.2 (9.8, 23.4) < 0.01
ǡȋȀ2)  23.6 ± 4.2 23.7 ± 4.6 0.38
ǡȋȌ 10.4 ± 4.9 10.4 ± 5.0 0.58
ǡȋȌ 115.6 ± 12.2 114.9 ± 12.2 0.02
ǡȋȌ 68.1 ± 9.5 67.6 ± 9.6 0.04
ǡǤȋΨȌ 1938 (46.2) 764 (35.2) < 0.01
ȀǡǤȋΨȌ 2683 (61.3) 1131 (50.6) < 0.01
ǡǤȋΨȌ 1897 (42.9) 1117 (45.9) 0.02
   Total energy intake, (kcal) 2051 ± 559 2018 ± 585 0.05
ǡǤȋΨȌ 1037 (26.1) 649 (30.3)                < 0.01
ǡǤȋΨȌ 2150 (54.7) 957 (45.5) <0.01
ǡȋȀȌ 18.5 ± 9.0 18.2±10.0 0.50
ǡȋρȀȌ 7.1 ± 1.9 7.6±2.3 <0.01
ǡǤȋΨȌ 80 (1.9) 66 (2.9) < 0.01

ǡǤȋΨȌ 170 (4.0) 70 (3.1) 0.06

ǡǤȋΨȌ 40 (0.9) 30 (1.3) 0.14
Childhood characteristics
	ǡȋȀȌ 7.9 (0.64, 38.40) 7.10 (1.9, 24.3) 0.95
Ǧ͸	ǡȋȀȌ 4.1 (0.03-28.89) 4.9 (0.91, 17.8) 0.48
Ǧ͵	ǡȋȀȌ 0.5 (0.00, 3.67) 0.5 (0.1, 2.08) 0.71
ǡǤȋΨȌ 2225 (49.9) 1274 (51.6) 0.18
   Gestational age at birth, (wk) 40.1 (35.7,42.4) 40.0 (35.0, 42.3) < 0.01
   Birth weight, (g) 3436 ± 551 3387 ± 579 < 0.01
ǡȋΨȌ 3275 (92.8) 1289 (90.8) < 0.01
ȋΨȌ
       < 3 months
       3-4.9 months
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Background and Aims: ȋ	Ȍ -
Ǥϐ-
	Ǧ
Ǥ     Ǧ͵ Ǧ͸ 	
levels during pregnancy with childhood lipids and insulin levels.
Methods and Results: In a population-based prospective cohort study among 3,230 












Ǧ    ȋP values <0.05). These associations 
Ǥ
Conclusions:   Ǧ͵	  ϐ  
ǦǡǦǡ
ǤǦ͸	ǡǦ͸	




Suboptimal maternal nutritional status during pregnancy is associated with an in-
creased risk of cardio-metabolic diseases in the offspring.1	
Ǥ2 During pregnancy, maternal 
 ǡ    ȋ	Ȍǡ     -
sanoid synthesis and lipid messengers for fetal development.3 Animal studies have 
	-
ǯϐǤ4,5 Among humans, studies 
ǦǡȋȌǡ
Ǧ͵	ǡǦȋȌǦǡ
lower triglycerides, and a lower risk of the metabolic syndrome, whereas higher 
ȽǦȋȌǡǦ͸	ǡ
ϐǤ6,7 A small study among 242 Dutch mother-child pairs 
       ȋȌǡ  Ǧ͵ 	ǡ
during pregnancy were associated with higher total-cholesterol and low-density-
 ȋȌǦ    Ǥ   ǡ  
   ȋȌǡ Ǧ͸	ǡ 
proinsulin levels.8ǡ
 ϐ ϐ 
risk of diabetes mellitus, showed inconsistent results.9-11ǡϐ-
Ǧ͵Ǧ͸	Ǧ
insulin metabolism remains unclear.12
ǡ  ǡ   Ǧ    
early pregnancy onwards among 3,230 mothers and their children, the associations 
Ǧ͵Ǧ͸	Ǧ
ǡ Ǧǡ Ǧǡ ǡ   Ǧ
Ǥ




This study was embedded in the Generation R Study, a population-based prospective 




 ȋ ͳͻͺǤ͹ͺʹȀʹͲͲͳȀ͵ͳȌǤ     Ǥ 
ʹ ͲͲʹʹ ͲͲ͸
in the study. In total, 8,879 mothers were enrolled during pregnancy, of whom 7,072 
	͸ǡͻʹͷ
born children. Childhood lipids, insulin, or c-peptide levels were available in 3,230 of 
ȋϐSupplemental Figure S3.4.1). Missing blood 
samples were mainly due to non-consent for venous puncture or crying of the child. 
Maternal fatty acid status 
Maternal non-fasting venous samples were drawn at a median gestational age of 20.5 
ȋͻͷΨǣͳ͹ǤͳǦʹͶǤͻȌǤ	ǡ
selected and transported to the Division of Metabolic Diseases and Nutritional Medi-
ǡǤǯǡǤ
 ǡ      	 
performed using gas chromatography by a sensitive and precise high-throughput 
method, suitable for large epidemiological studies, as previously described.14 Based 
ϐǡ	
have been associated with the risk of cardiovascular and metabolic outcomes in 
adults, and with pregnancy and fetal outcomes.8,15	









a fatty acids set against the total fatty acids concentrations.16
Ǧ͸ȀǦ͵	Ǥ
Childhood lipids and insulin measurements
 ͸ ȋͻͷΨǡͷǤ͸Ǧ͹ǤͻȌǡ ǦǡǦǡ 
ǦǡǡǦ-
cally from venous blood samples 30 minutes after the last meal using a Cobas 8000 






Information on maternal age, educational level, ethnicity, and parity, was obtained 
   Ǥ13     Ǥ 
on maternal smoking habits during pregnancy and folic acid supplement use was 
  Ǧ   Ǥ    
30 weeks of gestation was calculated as the difference between maternal weight 




birth was obtained from medical records.19,20 Information about breastfeeding, 
timing of introduction of solid foods and average TV watching time was obtained 
Ǥ21	ͳ͵ǡ
ʹͳͳǦ
of the study (n = 1,566).22
Statistical analysis
           
 Ǧ͵Ǧ͸	   Ǥ
      ǡ  ǡ ǡ
ǡǡǡ
supplement use, total caloric intake during pregnancy, pregnancy complications, 
ǯ ǡ  Ǧ Ǧ  ȋȌǡ
breastfeeding duration, timing of introduction of solid foods, and TV watching time. 
   ǯ  
͸  
Ǥ	ǡǦ-





bias associated with missing data and to maintain statistical power, we performed 
multiple imputations of missing covariates by generating 5 independent datasets 







Table 3.4.1  shows the maternal and childhood characteristics. Mean (SD) second 
Ǧ͵Ǧ͸	ͳͲͷǤͶȀȋʹ͹Ǥ͹Ȍ
͸ͲʹǤͺȀȋͺͻǤͲȌǡ (Table 3.4.2). Results from the non-response analy-
sis are given in Supplemental Table S3.4.1 and show that mothers who were not 
included in the analyses smoked more often during pregnancy and developed more 
often gestational hypertensive disorders as compared to those who were included 
ȋǦδͲǤͲͷȌǤ          Ǧ͵ 	
levels compared to those included (Supplemental Table S3.4.2). Correlation coef-
ϐ	Supplemental Table S3.4.3.
Table 3.4.1. Characteristics of mothers and their children (N =3,230)a
Value
Maternal characteristics
ǡȋȌǡȋͻͷΨȌ 31.0 (20.1, 39.4)













Birth and infant characteristics
ǡǤȋΨȌ 1650 (51.1)

ȋȌǡȋͻͷΨȌ 40.1 (35.8, 42.3)




Childhood outcomes at 6 years


















 Ǧ͵ 	 Ȍǡ     Ǧ  Ǥ
Ǧ͵	ǡ
Ǧǡ
       ȋ Ǧ
δͲǤͲͷȌǤ      
Ǧǡ Ǧ    ȋǣ ͲǤͲͶ ȋͻͷΨ ǣ
ͲǤͲͳǡͲǤͲͺȌǡͲǤͲ͸ȋͻͷΨǣͲǤͲʹǡͲǤͲͻȌͲǤͲͶȋͻͷΨǣͲǤͲͳǡͲǤͲͺǡȌ
   Ȍǡ    Ǧ 
ǤǦ
instead of childhood insulin levels (Supplemental Tables S3.4.4). Results did not 

Ǥ




	 708.3 ± 98.8 43.1 ± 2.0
Total n-3 PUFA 105.4 ± 27.7 6.5 ± 1.5
 5.1 ± 1.8 0.3 ± 0.1
 8.8 ± 5.5 0.5 ± 0.3
 12.1 ± 4.4 0.7 ± 0.2
 77.9 ± 20.5 4.8 ± 1.1
Total n-6 PUFA 602.8 ± 89.0 37.2 ± 2.5
 361.1 ± 63.5 22.3 ± 2.8

 1.5 ± 0.7 0.1 ± 0.1
 8.5 ± 1.9 0.5 ± 0.1

 61.0 ± 16.5 3.7 ± 0.7
    AA 156.4 ± 32.6 9.6 ± 1.6
    DTA 6.9 ± 2.2 0.4 ± 1.1
Ǧ͸ȀǦ͵	 6.1 ± 1.7 -
aValues represent means ± SDs.
ǣ ǣ  Ǣ ǣ ȽǦ Ǣ 






Maternal n-6 PUFAs with childhood lipids and insulin levels







ȋǣͲǤͲͶ ȋͻͷΨǣͲǤͲͳǡͲǤͲͺȌͲǤͲͷ ȋͻͷΨǣͲǤͲͳǡͲǤͲͺǡ Ȍ
      Ȍǡ     Ǧǡ
Ǥ
c-peptide levels instead of childhood insulin levels (Supplemental Tables S3.4.5). 
 
Ǥ
Table 3.4.3.  Ǧ͵	ȋα͵ǡʹ͵ͲȌa
Maternal n-3 PUFA 
in SDS
ȋͻͷΨϐȌ
Total-cholesterol Ǧ Ǧ Triglycerides Insulin
Ǧ͵	
b 0.04 (0.01, 0.08)* 0.06 (0.02, 0.09)* 0.02 (-0.02, 0.05) -0.03 (-0.07, 0.01) 0.05 (0.01, 0.08)*
Childhood BMI modelc 0.04 (0.01, 0.08)* 0.06 (0.02, 0.09)* 0.02 (-0.02, 0.05) -0.03 (-0.07, 0.01) 0.05 (0.01, 0.08)*

 -0.02 (-0.06, 0.02) -0.02 (-0.06, 0.01) -0.03 (-0.07, 0.01) 0.01 (-0.02, 0.05) -0.01 (-0.05, 0.03)
Childhood BMI model -0.02 (-0.06, 0.02) -0.03 (-0.06, 0.01) -0.03 (-0.07, 0.01) 0.01 (-0.02, 0.05) -0.01 (-0.04, 0.03)

 0.03 (-0.01, 0.07) 0.07 (0.03, 0.10)* 0.01 (-0.03, 0.04) -0.03 (-0.07, 0.01) 0.04 (-0.01, 0.07)
Childhood BMI model 0.03 (-0.01, 0.07) 0.07 (0.03, 0.10)* 0.01 (-0.03, 0.04) -0.03 (-0.07, 0.01) 0.04 (-0.01, 0.07)

 0.01 (-0.03, 0.04) 0.01 (-0.03, 0.04) -0.01 (-0.04, 0.04) -0.01 (-0.05, 0.02) 0.04 (0, 0.07)*
Childhood BMI model 0.01 (-0.03, 0.04) 0.01 (-0.03, 0.04) 0.01 (-0.03, 0.04) -0.01 (-0.05, 0.02) 0.04 (0.01, 0.08)*

 0.04 (0.01, 0.08)* 0.06 (0.02, 0.09)* 0.02 (-0.02, 0.06) -0.03 (-0.06, 0.01) 0.04 (0.01, 0.08)
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Maternal n-6/n-3 PUFAs ratio with childhood lipids and insulin levels 
Figure 3.4.1  shows that a higher Ǧ͸ȀǦ͵	







Table 3.4.4.  Ǧ͸	ȋα͵ǡʹ͵ͲȌa
Maternal n-6 PUFA 
in SDS
ȋͻͷΨϐȌ
Total-cholesterol Ǧ Ǧ Triglycerides Insulin
Ǧ͸	
2 0.01 (-0.03, 0.05) 0.01 (-0.03, 0.05) 0.02 (-0.02, 0.06) 0.02 (-0.02, 0.06) -0.02 (-0.06, 0.02)
Childhood BMI model 3 0.01 (-0.03, 0.05) 0.01 (-0.03, 0.05) 0.01 (-0.03, 0.05) 0.02 (-0.02, 0.06) -0.02 (0.06, 0.02)

 -0.01 (-0.05, 0.02) 0.01 (-0.03, 0.04) -0.01 (-0.04, 0.03) 0.01 (-0.03, 0.05) -0.02 (-0.05, 0.02)
Childhood BMI model -0.01 (-0.05, 0.03) 0.01 (-0.03, 0.04) -0.01 (-0.04, 0.03) 0.01 (-0.03, 0.05) -0.01 (-0.05, 0.02)


 -0.02 (-0.06, 0.02) -0.02 (-0.06, 0.01) -0.02 (-0.06, 0.02) 0.01 (-0.03, 0.04) 0.01 (-0.03, 0.04)
Childhood BMI model -0.02 (-0.05, 0.02) -0.02 (-0.06, 0.01) -0.02 (-0.05, 0.02) 0.01 (-0.03, 0.04) 0.01 (-0.03, 0.04)

 -0.02 (-0.06, 0.01) -0.04 (-0.07, -0.01)* -0.01 (-0.05, 0.02) 0.01 (-0.03, 0.05) -0.02 (-0.05, 0.02)
Childhood BMI model -0.02 (-0.06, 0.01) -0.04 (-0.07, -0.01)* -0.01 (-0.05, 0.02) 0.01 (-0.03, 0.04) -0.02 (-0.05, 0.02)


 -0.01 (-0.05, 0.03) -0.07 (-0.10, -0.03)* 0.01 (-0.04, 0.04) 0.06 (0.02, 0.10)* -0.03 (-0.06, 0.01)
Childhood BMI model -0.01 (-0.05, 0.03) -0.07 (-0.10, -0.03)* 0.01 (-0.04, 0.04) 0.06 (0.02, 0.09)* -0.03 (-0.06, 0.01)
AA
 0.04 (0.01, 0.08)* 0.05 (0.01, 0.08)* 0.03 (-0.01, 0.07) -0.02 (-0.06, 0.02) 0.02 (-0.01, 0.06)
Childhood BMI model 0.04 (0.01, 0.07)* 0.05 (0.01, 0.09)* 0.03 (-0.01, 0.06) -0.02 (-0.06, 0.01) 0.02 (-0.02, 0.05)
DTA
 -0.02 (-0.06, 0.02) -0.03 (-0.07, 0.01) 0.01 (-0.03, 0.04) -0.01 (-0.04, 0.03) -0.02 (-0.05, 0.02)
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in the follow-up studies at the age of 6 years. The non-response could lead to biased 
	
Figure 3.4.1.  Ǧ͸ȀǦ͵	ȋα͵ǡ͵ʹͲȌ


































x Adjusted model 








insulin levels would be different between children included and not included in the 
analyses. Non-response analysis showed that mothers included in the analyses had 
Ǧ͵	Ǧ͸ȀǦ͵	
included. It is hard to speculate whether these differences would have affected the 
 Ǥ     	
levels in plasma samples once during pregnancy. No information was available about 
	Ǥǡ	
ϐʹ-
sonable indicators for the recent intake.23 The fasting time before venous punctures 
was limited. Due to the young age of the children and the structure of the follow-up 
ǡ͵ǦǤ
blood samples obtained 30-minutes after the last meal to measure childhood lipids, 
ǦǤǦϐ
 	Ǥ 
shown among adult populations that also non-fasting lipid and insulin levels are 
associated with increased risks of cardiovascular events.24-26 Further studies are 
needed with more detailed fasting measurements of offspring lipids and insulin 
      	   
with both fasting and non-fasting offspring lipid and insulin metabolism throughout 
the life course. The percentages of women with gestational diabetes were relatively 
ǤϐǤ
Ǥ-
tunately, in our study, no data were available on glucose tolerance before and during 
ǡ     ϐ    
development of gestational diabetes. The prevalence in our study was lower than 
   ǡ      
gestational diabetes and the relatively healthy study population within our study 
cohort.27	ǡ
maternal and childhood confounders, residual confounding might still occur, as in 
any observational study.
ϐ
Suboptimal maternal nutritional status during pregnancy is associated with an in-
creased risk of cardio-metabolic diseases in the offspring.28,29
	-
tabolism, measured in cord blood.8,30,31ǡ




metabolism have shown inconsistent results. A study among 965 Danish pregnant 
Ǧ͵	
ǦǡǦǦ-





cholesterol, triglycerides, and lipoproteins in their 19-years-old offspring.9 A small 
study in 242 mother-child pairs from the Netherlands showed that a higher maternal 
ǡǦ͵	ǡϐ
 Ǧ  Ǧ   ͹ǦǦ Ǥ  
ǡǡǦ͸	ǡ-
Ǧǡ






 Ǧǡ    
ǦǦǤǡ
Ǧ͸ȀǦ͵	Ǧǡ
higher childhood triglycerides levels. These associations were independent of child-
Ǥǡ	
status during pregnancy is associated with childhood lipid levels, independent of 
ǤǦ͵Ǧ͸
	Ǥ
preferentially transferred from the maternal to the fetal circulation by means of a 
preferential placental transfer mediated by fatty acid transport and binding pro-
teins33,34   ϐ  
		Ǥ
    ϐ  	   
insulin sensitivity also reported inconsistent results.10,11,31 A randomized controlled 
  ͷ͵͵        Ǧ͵ 	 -
mentation during the third trimester of pregnancy on insulin levels in 19-year-old 




was associated with reduced risk of offspring type I diabetes mellitus.11 Another 
  Ͷ͹      ǡ 
Ǧ͵	ǡǡ-
pared to the control group.31 A study among 242 Dutch mother-child pairs showed 
ǡǦ͵	ǡ
͹ǦǦǡǡǦ͸	ǡ-
ǯǤ8 Contrary to these previous studies, 
Ǧ͵	ϐ
pregnancy were associated with higher childhood insulin and c-peptide levels, inde-
Ǥ
Ǧ͸	Ǥ
           ǡ
       	  
ȀǤ8-11,31,32 The previous 
studies all used fasting blood samples, whereas in our study we used non-fasting 
blood samples to measure childhood lipid and insulin metabolism.8-10,32 Thus far, it 
   	      
fasting vs non-fasting lipid and insulin metabolism. Further studies are needed to 
      	    
offspring fasting and non-fasting measures of lipid and insulin metabolism.
        Ǥ 
  ǡ
          ϐ 
ǤǦ͵	
offspring total-cholesterol and triglycerides through a reduction of hepatic synthesis 
of triacylglycerols and very-low-density-lipoprotein.35 Furthermore, as a part of the 
ǡǦ͵	
b-cells directly by altering lipid raft structure.36Ǧ͸	ǡ
ϐ-
          ǡ 
    ϐ Ǥ37,38 	   
offspring insulin levels during pregnancy through epigenetic regulation of imprinted 
genes, especially insulin growth factor 2 (IGF2), which is known to control fetal 
ǡȀǤ39 Future research focused on 
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epigenetic regulation of imprinted genes, including IGF2, which may be involved in 
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Figure S3.4.1.  Flow chart of the participant

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Mothers with available fatty acids 
measurements in mid-pregnancy  
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Excluded due to twin birth and 	lost to 
follow up  
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Mothers with singleton live births  














































































Excluded due to missing no participation at 
focus at 5 measurements or no lipid levels, 
insulin or c-peptide measurement available 	
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͵ǤͶ
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ǡȋȌǡȋͻͷΨȌ 31.0 (20.1, 39.4) 29.6 (18.9, 38.9) 0.1

ǡȋȌǡȋͻͷΨȌ 20.5 (17.1, 24.9) 20.5 (18.5, 23.6) 0.04
ǦǡȋȀʹȌǡȋȌ 23.6 (4.2) 23.7 (4.5) 0.69
ǡȋȌǡȋȌ 10.4 (4.9) 10.3 (5.2) <0.01
ǡǤȋΨȌ 1455 (47.7) 1247 (37.5) <0.01
ǡǤȋΨȌ 1963 (61.9) 1851 (53.8) 0.04
ǡǤȋΨȌ 1808 (56.3) 2036 (55.8) <0.01
ǡǤȋΨȌ 736 (25.6) 950 (29.4) 0.30
	ǡǤȋΨȌ 1867 (75.7) 1838 (67.8) <0.01

ǡǤȋΨȌ 27 (0.9) 43 (1.2) 0.11

ǡǤȋΨȌ 176 (5.6) 210 (5.9) 0.17
Birth and infant characteristics
ǡǤȋΨȌ 1650 (51.1) 1850 (50.1) 0.51

ȋȌǡȋͻͷΨȌ 40.1 (35.8, 42.3) 40.1 (35.0, 42.4) <0.01
Breastfeeding duration (months), mean (SD) 4.5 (3.9) 4.1 (3.8) <0.01
ǤȋΨȌε͸ 208 (10.1) 185 (10.8) 0.84
Ǧ͵	ȋȀȌ 0.6 (0.4) 0.6 (0.4) 0.5
Ǧ͸	ȋȀȌ 4.7 (3.0) 4.9 (3.3) 0.31
Childhood outcomes at 6 years
͸ȋȀ2), mean (SD) 16.2 (1.8) 16.2 (1.9) 0.45
ǡǤȋΨȌ
δʹȀ 2059 (80.6) 1326 (81.6)
0.50




Table S3.4.2.  	
the analyses (N=3,320)a




No participation in 
follow-up
N = 2,094 P-value
	
ȋȀȌ 708.3 ± 98.8 702.0 ± 100.7 <0.01
ȋΨȌ 43.1 ± 2.0 43.3 ± 2.1 <0.01
Ǧ͵	
ȋȀȌ 105.4 ± 27.7 101.7 ± 26.9 <0.01
ȋΨȌ 6.5 ± 1.5 6.3 ±1.4 0.6

ȋȀȌ 5.1 ± 1.8 4.9 ± 1.9 <0.01
ȋΨȌ 0.3 ± 0.1 0.3 ± 0.1 0.1

ȋȀȌ 8.8 ± 5.5 8.1 ± 5.2 <0.01
ȋΨȌ 0.5 ± 0.3 0.5 ± 0.3 0.5

ȋȀȌ 12.1 ± 4.4 11.8 ± 4.3 <0.01
ȋΨȌ 0.7 ± 0.2 0.7 ± 0.2 0.8

ȋȀȌ 77.9 ± 20.5 75.3 ± 20.0 <0.01
ȋΨȌ 4.8 ± 1.1 4.7 ± 1.1 0.4
Ǧ͸	
ȋȀȌ 602.8 ± 89.0 604.3 ± 89.5 <0.01
ȋΨȌ 37.2 ± 2.5 37.6 ± 2.5 <0.01

ȋȀȌ 361.1 ± 63.5 361.8 ± 62.3 <0.01
ȋΨȌ 22.3 ± 2.8 22.5 ± 2.8 0.4


ȋȀȌ 1.5 ± 0.7 1.5 ± 0.7 <0.01
ȋΨȌ 0.1 ± 0.1 0.1 ± 0.0 <0.01

ȋȀȌ 8.5 ± 1.9 8.5 ± 1.9 <0.01
ȋΨȌ 0.5 ± 0.1 0.5 ± 0.1 <0.01


ȋȀȌ 61.0 ± 16.5 60.1 ± 17.1 <0.01
ȋΨȌ 3.7 ± 0.7 3.7 ± 0.8 0.1
AA
ȋȀȌ 156.4 ± 32.6 157.2 ± 32.9 <0.01
ȋΨȌ 9.6 ± 1.6 9.8 ± 1.6 0.1
DTA
ȋȀȌ 6.9 ± 2.2 7.1 ± 2.2 <0.01
ȋΨȌ 0.4 ± 1.1 0.4 ± 0.1 0.1
Ǧ͸ȀǦ͵	
ȋȀȌ 6.1 ± 1.7 6.3 ± 1.7 0.2
ȋΨȌ - -



























 0.38* 0.33* 1
 0.22* 0.77* 0.27* 1
 0.38* 0.65* 0.35* 0.48* 1
 0.46* 0.97* 0.21* 0.65* 0.51* 1
Total n-6 
PUFA 0.96* 0.22* 0.31* 0.00 0.21* 0.21* 1
 0.81* 0.08* 0.35* -0.07* 0.07* 0.07* 0.87* 1

 0.35* 0.16* 0.20* 0.12* 0.27* 0.10* 0.34* 0.10* 1
 0.58* 0.11* 0.28* -0.06* 0.13* 0.11* 0.61* 0.62* 0.14* 1

 0.60* 0.22* 0.30* 0.10* 0.32* 0.16* 0.59* 0.32* 0.51* 0.50* 1
AA 0.65* 0.32* 0.00 0.11* 0.23* 0.35* 0.62* 0.21* 0.36* 0.11* 0.36* 1
DTA 0.45* 0.03 0.08* -0.11* 0.32* -0.01 0.49* 0.16* 0.51* 0.27* 0.55* 0.57* 1
aϐǤȗǦδͲǤͲ͸Ǥ
ǣ ǣ ȽǦ Ǣ ǣ  Ǣ 




Table S3.4.4.  Ǧ͵	Ǧȋα͵ǡʹ͵ͲȌa
Maternal n-3 PUFA in SDS ǦȋͻͷΨϐȌ
SDS
Ǧ͵	
2 0.04 (0, 0.08)*
Childhood body mass index 3 0.04 (0.01, 0.08)*

 -0.01 (-0.04, 0.03)
Childhood body mass index -0.01 (-0.04, 0.04)

 0.02 (-0.02, 0.06)
Childhood body mass index 0.02 (-0.02, 0.06)

 0.03 (-0.01, 0.07)
Childhood body mass index 0.03 (-0.01, 0.07)

 0.04 (-0.01, 0.07)
Childhood body mass index 0.04 (0, 0.07)*
aϐȋͻͷΨȌϐǦ
Ǧ͵	ǡǤ








Table S3.4.5.  Ǧ͸	Ǧȋα͵ǡʹ͵ͲȌa
Maternal n-6 PUFA in SDS
ǦȋͻͷΨϐȌ
Ǧ͸	
2 -0.02 (-0.06, 0.02)
Childhood BMI model 3 -0.02 (-0.06, 0.02)

 -0.01 (-0.05, 0.03)
Childhood BMI model -0.01 (-0.05, 0.03)


 0.01 (-0.02, 0.05)
Childhood BMI model 0.01 (-0.02, 0.05)

 -0.01 (-0.05, 0.02)
Childhood BMI model -0.01 (-0.05, 0.02)


 -0.01 (-0.05, 0.02)
Childhood BMI model -0.01 (-0.05, 0.02)
AA
 0 (-0.04, 0.04)
Childhood BMI model -0.01 (-0.04, 0.03)
DTA
 -0.02 (-0.05, 0.02)
Childhood BMI model -0.02 (-0.05, 0.02)
aϐȋͻͷΨȌϐǦ
Ǧ͸	ǡǤb ǡ ǡǡǡǦ
 ǡ ǡ    
ǡ  ǯ ǡ  Ǧ  Ǧ ǡ  ǡ  















Cardio-metabolic disease is the leading cause of death worldwide.1 The develop-
mental origins hypothesis proposes that cardio-metabolic disease at least partly 
originates during early life.2 This hypothesis suggests that adverse factors during 
pregnancy may adversely affect the fetal development, and thereby increase the risk 
of developing diseases later in life.
ϐ
the composition and distribution of fetal tissues and lead to alterations in cardio-
metabolic structure and function.3 The Dutch famine study showed that severe fetal 
undernutrition in different periods of pregnancy may lead to an increased risk of 
obesity and coronary heart disease in later life.4ǡ  
ϐ      Ǥ   
acids are important for fetal growth and development.5 Fatty acids are natural com-
ponents of fats and oils and are derived from triglycerides or phospholipids. Based 
on their chemical structure they can be differentiated into groups: saturated fatty 
ȋ	Ȍǡȋ	Ȍ
ȋ	ȌǤ		ǡ	
provided by placental transfer because humans cannot synthesize them. Therefore, 
	
and development.6  	   ǡ    
  
Ǥϐ
associated with adverse maternal and fetal pregnancy outcomes.7,8ǡ
ϐ
term offspring cardio-metabolic health.
            ϐ 
maternal fatty acid levels measured in mid-pregnancy on cardio-metabolic health 
outcomes in mothers and their children. This chapter provides a general discussion 
ϐ-





Prepregnancy body mass index, gestational weight gain and fatty acid
ǡ
associated with adverse maternal and fetal pregnancy outcomes.9  ǡ -
cessive gestational weight gain has been linked to complications during pregnancy, 
including diabetes mellitus, gestational hypertensive disorders and delivering large 
size for gestational age infants.10
gestational weight gain are associated with an increased risk of childhood obesity 
ǦϐǤ11 
A growing body of evidence indicates that increased body weight during pregnancy 
    Ǥ  
higher circulating free fatty acid levels caused by dyslipidaemia and insulin resis-
tance.12 Results from previous studies among adults have shown that a higher body 
	ǡǦ͵	
  Ǧ͸ȀǦ͵ 	 Ǥ13,14 A previous study suggested that women who 
 	   Ǧ͵	















 ȽǦ     
Ǧ͸	
   Ǧ͸	ǦɀǦ  






The mechanisms underlying the association between prepregnancy body mass 
ǡ           
unknown. Several mechanisms may be involved. Increased prepregnancy weight 
may alter the absorption and metabolism of circulating fatty acid levels.15 Also, the 
diet composition of overweight and obese women during pregnancy may differ 
comparted to normal weight women with larger amounts of food high in total fat 
	Ǥǡ
functioning and energy metabolism leading to increased risk of obesity throughout 
pregnancy.16
ǡ




decreases in systemic vascular resistance and an increase in maternal cardiac output 
and total blood volume.17ǡ-
sia and gestational hypertension are associated with increased risk of maternal and 
perinatal morbidity and mortality.18
    ϐ    
Ǥǡ   ϐǡ
		ǡ-
vascular disease.19,20 Results from observational and randomized controlled studies 
     Ǧ͵ 	    
 ǡ 	Ǧ͸	
associated with an increased risk of preeclampsia.21,22 Not much is known about the 
effect of maternal fatty acids status on blood pressure development and placental 
function throughout pregnancy. Alterations in maternal hemodynamic adaptations 
during pregnancy may partly underlie the observed associations with gestational 
hypertensive disorders.
Table 4.1. ǡ
Exposure Fatty acid levels during pregnancy 
 ൹SFA ൻǦ͵	 ൹Ǧ͸	




ing pregnancy affect maternal blood pressure development, umbilical and uterine 
artery resistance indices and the risk of gestational hypertensive disorders. Results 
   	ǡ	ǡ
      ϐ  Ǥ 
Ǧ͵Ǧ͸	-
tions were associated with a lower blood pressure throughout pregnancy. Fatty acid 




pressure levels throughout pregnancy and might also increase the risk of gestational 
hypertensive disorders (Table 4.2).
        ϐ  
adaptations are not well understood. First, it has been suggested that higher SFAs 
are associated with a higher blood pressure by impairing endothelial function with 
higher levels of cholesterol which accumulate in the arterial walls and with increased 
ǤǦ͵	-
lated to increased production of vasodilators such as prostaglandin I
3





pressure.25 Second, adverse fatty acid levels might contribute to placental dysfunction 
and might damage uteroplacental tissues by increasing production and secretion of 
 ϐ       
Ǥ26,27 	ǡ ǡ-
ǡǡǦ
activated receptors, they are known to be important for placental development and 
ǡϐǤ28 In this study we 
Ǣ
ǤǡǦ͵	-
Table 4.2. Fatty acids and hemodynamic adaptations during pregnancy
Exposure Maternal hemodynamic adaptations






 ǡ   
seen in gestational hypertensive disorders because of their role during pregnancy 
ϐǡǤ29 In contrary, 
ϐ  ǡ Ǧ͸	ǡ
Ǥ25 Finally, the observed associations may be 
ǦǤǡ
Ǥǡ
issue. Future studies are needed to obtain further insight into these associations, the 
underlying mechanism and causality. 
Childhood outcomes 
Fetal life is an important period for the development of cardio-metabolic diseases 
Ǥ	ǡǦ͵Ǧ͸	-
nancy and might be involved in fetal development and childhood cardio-metabolic 
risks.5
Childhood adiposity
The prevalence of childhood obesity has increased dramatically over the past sev-
eral decades.30      
cardio-metabolic diseases in later life, including elevated blood pressure, dyslipid-
emia, metabolic syndrome, and diabetes mellitus.31 There is accumulating evidence 
         ϐ 
Ǥ
     Ǥ	ǡ 
Ǧ͵Ǧ͸	ǡ-
	ϐ
of body composition in the offspring.32,33Ǧ͵	ǡ
   ǡ    ǡ












sorptiometry (DXA) and pre-peritoneal abdominal fat area measured by ultrasound, 
ǤǦ͵




  ͳǡʹͷͲ Ǧ      
eicosapentaenoic acid concentrations were associated with a lower subcutaneous 
fat mass at the age of 3 years.32Ǧ͸	
ǦɀǦ
ǡȀ
Ǧ  ǡ   Ǥ
          Ǧ
  Ǧ Ǥ  ϐ   
 Ǧ͵ 	     Ǧ͸ 	   
pregnancy are associated with higher total body fat and abdominal fat levels in child-
hood (Table 4.3). 
Childhood blood pressure




later in life.40 Not much is known about the associations of different maternal n-3 and 
Ǧ͸	Ǥ
 ϐǦ͵Ǧ͸	  
Ǧ͸ȀǦ͵	-
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positively associated with childhood systolic blood pressure, but not with childhood 
 Ǥǡ   Ǧ͸ȀǦ͵	 
associated with higher childhood systolic blood pressure. These associations were 
Ǥϐ-
ϐǦ͵	Ǧ͸	
concentrations  during mid-pregnancy are associated with a lower systolic blood 
pressure in childhood. Thus, increased blood pressure later in life may be associated 
  Ǧ͵Ǧ͸	ǡ
Ǧ͸ȀǦ͵	ȋTable 4.4).
Childhood lipids and insulin levels
ϐ
life have been recognized as important risk factors for cardio-metabolic disease later 
in life.41 Animal studies have shown that a maternal diet containing higher levels of 
	ǯϐ
in the postnatal period.42-46 ǡ    
ϐǦ͵Ǧ͸	
on long-term offspring lipid and insulin metabolism. 
ǡǦ͵Ǧ͸	
pregnancy are associated with childhood lipids and insulin levels. In this thesis we 
Ǧ͵	
ǦǡǦ
and insulin levels. In addition, higher maternal eicosapentaenoic acid levels were as-
Ǧǡ






levels of maternal docosapentaenoic acid during pregnancy were associated with 
ǦǦǤ46-
Table 4.4. 	
Exposure Childhood blood pressure 
Ǧ͵	 ൻSystolic blood pressure 
Ǧ͸	 ൹Systolic blood pressure
Ǧ͸ȀǦ͵	 ൹Systolic blood pressure
Ͷ
 !
nal arachidonic acid levels were associated with lower childhood triglycerides and 
ǦǡǦ͸	Ǥ
Another small study performed among 259 children suggests that higher availability 
 ɀǦ ǦɀǦ     
levels of plasma triacylglycerol and insulin resistance.47 The observed associations 








metabolism (Table 4.5). 
Underlying mechanisms 
ǡ Ǧ͵Ǧ͸	ϐ  
maternal diet as it affects different components of fetal development, including struc-
tures of the cell membranes, organs function and metabolism.48 Among n-3 and n-6 
	ǡǦ-
tion and desaturation of these fatty acids in the human body, a series of longer-chain 
ǡǤ48 
   ϐ   
Ǧ͵	Ǧ͸	Ǥ
Ǧ͵Ǧ͸	
and childhood cardio-metabolic outcomes. 
  Ǧ͵ Ǧ͸	  -
tiation of fetal adipose cells through their role as precursors of eicosanoids such as 
ǡǤ49Ǧ͵	-
ine monophosphate  production through prostaglandins, leading to inhibition of fetal 
adipocytes differentiation.50  ǡ  Ǧ͸	ǡ
appears to be highly adipogenic promoting the differentiation of fetal preadipocytes 
into mature and functional adipocytes.49Ǧ͵	
Table 4.5. 	
Exposure Childhood lipids and insulin levels
Ǧ͵	 ൹Total cholesterol ൹Ǧ ൹Insulin




during pregnancy, which inhibit differentiation of adipocyte cells, were associated 
ǤǡǦɀǦ
acid levels, which stimulate the proliferation of fetal adipocytes, were associated 
with higher childhood fat mass.  
    Ǧ͵ 	   Ǧ͸	 
during pregnancy were associated with a lower systolic blood pressure in childhood. 

Ǥ    Ǧ͵	   -
proved fetal endothelial vasodilator function and reduced pressor reactivity of resis-
tance vessels.51
responses by attenuating constrictor responses to noradrenaline, in relation with 
a decrease in plasma norepinephrine which mechanism might be responsible for a 
reduction in blood pressure.52 In addition, they have hypotensive properties through 
       ǡ 
          
hormones.53-55ǡǦ͵	  
triphosphate release from the endothelium and increase vasodilation by stimulating 
Ǥ56ǡǦ͸	
ǡ
stimulate offspring vasoconstriction and increase offspring blood pressure.57 
       Ǧ͵ 	  ϐ 
levels during pregnancy are associated with higher childhood total-cholesterol, 
Ǧ   Ǥ   Ǧ͸ 	ǡ  
Ǧ͸	ǡ
Ǥϐ-
bolic outcomes might be through epigenetic mechanisms or structural adaptations 
that lead to changes in biological mechanisms of liver and adipose tissue which are 
strongly associated with development of dyslipidemia, insulin resistance, and car-
diovascular diseases. Some other mechanisms have also been proposed. The lipid 
Ǧ͵	
of triacylglycerol and very-low-density-lipoprotein.58 As a part of the cell membrane, 
Ǧ͵	
pancreatic b-cells directly by altering lipid raft structure.59Ǧ͸	
the lipid metabolism and change the fatty liver content by increasing blood levels of 






ϐǤ  Ǧ͸	  Ǧ͵	  
      Ǧϐǡ  
Ǥϐǡ
  Ǧ͵ 	ǡ    Ǧ͸ȀǦ͵ 	  
ϐ Ǧ Ǥǡ 
observational design, residual confounding due to unmeasured maternal and child-
hood socio-demographic and lifestyle related determinants might still be an issue. 
Thus, further research using sophisticated study designs, including randomized con-




been described in Chapter 2 and Chapter 3 of this thesis. In the following para-
graphs, general methodological considerations regarding selection bias, information 
bias and confounding are discussed.
Selection bias
Selection bias may occur if the association between the determinant and outcome 

  Ǥ  ǡ͸ͳΨ 
the study area participated at birth in the Generation R Study. This non-response 
due to non-participation and missing values at baseline among the participants is 
not likely to be at random. The percentages of women from ethnic minorities and 
Ǧϐ
in Rotterdam.60 Also, the percentages of women with gestational hypertension and 
preeclampsia, or children born preterm or with a low birth weight were lower, which 





in association studies are not markedly affected by selective non-participation at 
baseline in large cohort studies.61,62
Selection bias in our studies might also occur due to selective loss to follow-up 




analyses, but this seems unlikely since loss to follow-up at birth in the presented 
studies was low. At the age of 6 years, children and their mothers were invited to 
participate in detailed body fat and cardio-metabolic follow-up measurements. 
Ǧ͹ͲΨǤ
children participated in blood sample measurements at the age of 6 years, which 
was mainly due to non-consent for venous puncture or crying of the child. Mothers 

 ǡ   Ǧ͵ 	    Ǧ͸ȀǦ͵ 	  
Ǥǡ
follow-up towards a more healthy population may have affected the effect estimates 
ǡϐǤ
Information bias






and this type of measurement error may lead to either overestimated or underesti-
mated effect estimates.63 ǡ 
and before assessment of the outcomes. Also, both mothers and their children were 
    ϐ      Ǥ 
ϐǤ
Ǧϐ      ǡ  
ǦϐǤ Ǧ-
ϐǡǤ
Self-reporting is a common approach for gathering data in epidemiologic and medi-
ǤǦϐ
Ǥ	ǡǡ
     -
nancy was self-reported. Self-reported weight tends to be underestimated especially 
in case of higher maternal weight, which might have led to an underestimation of 
       -
tational weight gain. In most of the studies presented in this thesis, the outcome 
was assessed using medical records, well-trained research nurses or standardized 
hands-on assessments of body composition and cardio-metabolic development. 
Ͷ
 
	ǡ        ǡ
ϐǤ
Confounding
           
dependent variable and the independent variable, and this variable is not an inter-
          Ǥ63 
The observational design of the study, such as the Generation R Study, also increases 
the risk of confounding. If a confounding factor is not taken into account, this may 
lead to a biased effect estimate of the association between the determinant and the 
outcome. To control for confounding in this thesis, we had information available on 
Ǥ
literature, their associations with the outcomes of interest or a change in effect esti-
ͳͲΨǤ
on childhood cardio-metabolic outcomes, for which we had information on multiple 
maternal and childhood socio-demographic and lifestyle related characteristics. 
ϐ
the results could be confounded by similarities between maternal diet in pregnancy 
ǯǤ

	 ͳ͵  	
intake in infants did not materially affect the observed associations. Nevertheless, as 
in all observational studies, results could still be affected through residual confound-
ing by unmeasured confounders or imperfect measurement of measured confound-
ers. Residual confounding may have led to an overestimation of the observed effect 
Ǥ    ǡ 
confounders only moderately affected the effect estimates, which suggest that the 




ous studies have shown that clinical manifestations of cardio-metabolic diseases 
occur mainly in adulthood, but the onset of these diseases may occur early in life.64-
66           




more insights in the effects of maternal fatty acids on early development of cardio-
Ǥǡ
associations were small, and are mainly of interest from a developmental perspec-
ǤǡǦ
childhood may be related to the development of cardio-metabolic disease in later 
life. It is important to perform long-term follow-up studies from early life into young 






cardio-metabolic development and that simultaneously affect fatty acids status 
should also be taken into account when assessing these associations. Therefore, 
further studies with more than one measurement of fatty acids status during preg-
nancy and controlling for other nutrients status are needed. It is also not possible to 
	
Ǥ	
fetal circulation by the placenta occurs via several mechanisms including passive and 
facilitated diffusion.
Main maternal outcomes studied in this thesis were maternal blood pressure de-
velopment, and umbilical and uterine artery resistance indices. The mechanisms by 
which fatty acids affect blood pressure during pregnancy remain controversial and 
	ǡ		
placental vascular development. Further research is needed to address the effect 

measurements in higher risk populations.  Main childhood outcomes were childhood 
blood pressure, body composition and cardio-metabolic biomarkers. Further addi-
tional measurements of childhood body composition and cardio-metabolic develop-
ment might provide further insight in the underlying mechanism linking maternal 
Ǧ
ǤǦǦǦȋȌǡ
            
	ϐǤ	
studies are needed for replication. In the pathogenesis of atherosclerosis, endothelial 
dysfunction and impaired vascular reactivity induced by dyslipidemia play an impor-
Ǥ
may be used as preclinical markers of atherosclerosis. The microvasculature is an 
Ͷ
 
    Ǥ     
Ǥǡǡ-
netic resonance imaging, are of interest to obtain further insight in detailed body 
Ǥǡǡ
coronary circulation magnetic resonance imaging, are of interest to obtain further 
insight in detailed cardiovascular development. 
Due to the observational design of our studies, we cannot establish causality of 
Ǥ ǯFADS1 or 
FADS2 genes, which encode for desaturase enzymes involved in the conversion of 
	Ǥǡ-
sality for the observed associations. These studies use genetic variances, which are 
-
ǡ      Ǥ
          Ǥ 
   Ǧ͵	
with childhood adiposity and have found no association.67,68 The INFAT randomized 
Ǧ͵	-
ǡǦ͸	ǡ
    ϐ Ǥ36 A 
randomized controlled trial among 533 pregnant Danish women showed no effects 
Ǧ͵	-
els in 19-year-old offspring.69 No randomized controlled trials have been conducted 
focused on fatty acids levels during pregnancy and pregnancy complications. Most 
of previous clinical trials had small sample sizes and confounding might still have 
ϐ
ǤǡǦ
establish whether fatty acid levels during pregnancy affect maternal and childhood 
outcomes. More evidence is needed to make proper recommendations for fatty acids 
consumption during prenatal care. 
Clinical implications
ϐϐ
  Ǧ Ǥ  ϐ    
ϐ  Ǧ        -
Ǥϐǡ




women and childhood development. Cardio-metabolic prevention strategies should 
start as early in life as possible and should focus on maternal nutritional status dur-
    ϐǤ ǡ   
         
consumption of maternal fatty acids.
References
 ͳǤ   ǡ  Ǥ 









      ǣǤǤ
ʹͲͲͳǢͳͺͷǣͻ͵ǦͺǤ
 ͷǤ  ǡ









































 ͳͺǤ     Ǥ   Ǧ     
ǤǤʹͲͳͲǢʹͳǣͳͳͺǦʹ͵Ǥ
 ͳͻǤ  ǡ Ǧ ǡ  ǡ 
 ǡ  ǡ 	 ǡ  ǡ    


























 ͵ͲǤ  Ǥ        Ǥ    Ǥ
ʹͲͳʹǢͳ͸ǣͳ͵ǦͻǤ
 ͵ͳǤ 	 ǡ  ǡ  ǡ     



































Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure 
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Chapter 1 describes the background and hypothesis for the studies presented in this 
ǤǦǤ
developmental origins hypothesis proposed that cardio-metabolic disease originate 
during intrauterine development. This hypothesis suggests that risk factors during 
pregnancy may adversely affect the fetal development, and thereby increase the risk 
of developing diseases later in life.
          -
  ǦǤ  ϐǡ 
     ǡ      




    ϐ   
cardio-metabolic diseases from early life onwards is important for future preventive 
strategies that aim to improve cardio-metabolic health throughout the life course. 
Therefore, studies presented in this thesis were designed to relate maternal fatty 
acid levels measured in mid-pregnancy with cardio-metabolic outcomes in mothers 
and children. 
The studies presented in this thesis were embedded in the Generation R Study, a 
population-based prospective cohort study from fetal life onwards in Rotterdam, The 
Netherlands. The Generation R Study is designed to identify early environmental and 
genetic determinants of growth, development and health in fetal life and childhood.
In Chapter 2ǡ
weight gain during pregnancy with different group of fatty acid concentrations  are 
described. Furthermore, fatty acids during pregnancy and hemodynamic adaptations 






of maternal fatty acid levels with maternal blood pressure development, umbilical 
and uterine artery resistance indices and the risk of gestational hypertensive disor-




concentrations  were associated with a lower systolic and diastolic blood pressure 
 Ǥ  	      
   ǡǦ͵Ǧ͸	-
Ǥ	
concentrations  were associated with the risk of gestational hypertensive disorders. 
ϐǡ-
tions  may lead to hemodynamic maladaptations and increased risks of gestational 
hypertensive disorders.
In Chapter 3,     	    
cardio-metabolic risk factors in childhood are described. In Chapter 3.1, -
	
subcutaneous fat mass. Total subcutaneous fat and central-to-total subcutaneous fat 
ͳǤͷǡ͸ʹͶǤǦ͵	
levels were associated with a higher central subcutaneous fat mass at 1.5 months, 
but with lower central subcutaneous fat mass at 6 months. No consistent associa-
Ǧ͸	
ǤǦ
or lifestyle related characteristics or birth characteristics. Therefore, maternal n-3 
	Ǥ
   	    
have persistent effects on growth and adiposity in the childhood (Chapter 3.2). At 
the age of 6 years, detailed total and abdominal body fat distribution measurements 




      Ǧ͵ 	  





body fat and abdominal fat levels in childhood.
In Chapter 3.3ǡ      	 
during pregnancy with childhood blood pressure. At the age of 6 years systolic and 
diastolic blood pressure was measured four times with one-minute intervals using a 
ǤǦ͵	










ǦǡǦ   Ǥ  Ǧ͸
	ǡǦ͸	ǡ
lipids and insulin levels. These results were not materially affected by additional 
Ǥ	
ϐǤ




pregnancy are associated with maternal and childhood cardio-metabolic outcomes. 
Although the observed associations were relatively small to moderate, they may be 
ǦǤϐǡ
  ϐ    
and child health. Cardio-metabolic prevention strategies should start as early in life 
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  Ǥ  Ǯ ǯ   
  Ǥ
         
ontwikkeling van de foetus op een ongunstige manier beïnvloeden, en daarmee het 
Ǥ











    Ǥ        
ǡ 
tweede trimester van de zwangerschap, te relateren aan cardiometabole gezond-
heidsuitkomsten in zowel moeders als hun kinderen.
De studies die beschreven worden in dit proefschrift maken deel uit van het Gen-
eration R onderzoek, een populatie-gebaseerd prospectief cohortonderzoek, in Rot-
ǡǡǤ
Generation R onderzoek is opgezet om vroege omgevings- en genetische factoren 
 ϐ        ǡ   
Ǥ





totale verzadigde vetzuurconcentraties en hogere totale omega-6 meervoudig on-
Ǥ





        ϐǤ

bloeddruk ontwikkeling, de vaatweerstand van de arteria umbilicalis en de arteria 
uterina en het risico op pre-eclampsie en zwangerschapshypertensie onderzocht 
(hoofdstuk 2.2ȌǤǡ
maar niet meervoudig onverzadigde verzuurconcentraties, geassocieerd waren 
met een hogere bloeddruk, en dat hogere totale omega-3 meervoudig onverzadigde 
vetzuurconcentraties en omega-6 meervoudig onverzadigde vetzuurconcentraties 

  Ǥ     -
socieerd met een lagere placentaire vaatweerstand, hogere omega-3 en omega-6 
meervoudig onverzadigde vetzuren waren geassocieerd met een hogere placentaire 
vaatweerstand. Alleen hogere maternale verzadigde vetzuurconcentraties waren 
    Ǧ  Ǥ 
-
ǡ		ǡ
kunnen leiden tot ongunstige hemodynamische aanpassingen en een verhoogd risico 
op pre-eclampsie of zwangerschapshypertensie.  
In hoofdstuk 3-
zadigde vetzuurconcentraties met verschillende risicofactoren voor cardiometabole 




maternale omega-3 meervoudig onverzadigde vetzuurconcentraties geassocieerd 
ͳǤͷǡ
͸Ǥ
consistente associaties tussen maternale omega-6 onverzadigde vetzuurconcentra-
 Ǥ
        -
merken. Maternale omega-3 meervoudig onverzadigde vetzuurconcentraties zouden 

 Ǥ     
 
het kind (hoofdstuk 3.2ȌǤ͸




omega-3 meervoudig onverzadigde verzuurconcentraties en hogere omega-6 onver-

hoger percentage lichaamsvet en een ongunstige totale en abdominale vetverdeling 
ǤǤ
De gevonden associaties werden deels verklaard door verschillen in andere ken-




In hoofdstuk 3.3 hebben we gekeken naar de associaties van maternale meer-
 -
Ǥ͸
     ͳ    -
  Ǥ      Ǧ͵
meervoudig onverzadigde vetzuurconcentraties en lagere omega-6 meervoudig 
      
 ͸Ǧ Ǥ
werden maar deels verklaard door verschillen in andere kenmerken van moeder 
en kind. Deze resultaten suggereren dat maternale inname van meervoudig onver-
     
ǡǤhoofdstuk 3.4 
hebben we onderzocht of maternale omega-3 en omega-6 meervoudig onverzadigde 
    Ǧ    
haar kind. Na correctie voor potentiele confounders waren hogere maternale totale 
Ǧ͵ǡǡ
     ǡ Ǧ 
Ǥ Ǧ͸
vetzuurconcentraties, maar niet totale omega-6 concentraties, waren geassocieerd 
 Ǧ   Ǥ    
       Ǥ   
        
lipiden- en insuline metabolisme van het kind. 
In hoofdstuk 4 geven we een algemene discussie waarin de studies beschreven in 
ǡ-
ties voor toekomstig onderzoek gegeven. 
Concluderend, de bevindingen van dit proefschrift suggereren dat maternale vet-

































DTA docosatetraenoic acid 

















RCT randomized controlled trial
SD standard deviation
SDS standard deviation score
SFA saturated fatty acid
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“Well, maybe it started that way. As a dream, but 
doesn’t everything. Those buildings. These lights.  
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And maybe that is what I did. I dreamed about coming 
here, but then I did it.” 
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